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ABSTRACT 
As an increasing number of individuals reach advanced age, cognitive impairment and 
dementia are growing public health problems and thus, there is a growing demand to 
identify modifiable risk factors for these disorders. Cognitive impairment and Alzheimer’s 
disease (AD), the most common cause of dementia, have recently been shown to share 
many risk factors with cardiovascular diseases. However, the specific role of various 
vascular risk factors for cognitive functioning is still unclear. 
The aim of the thesis was to elucidate the role of novel cardiovascular risk indicators for 
cognition in the general population. The specific aims were to investigate the associations 
of metabolic syndrome, high sensitivity C-reactive protein, peripheral atherosclerosis as 
well as that of brain-derived neurotrophic factor with the risk of suffering cognitive 
impairment. The main outcome, cognitive function was assessed using both global and 
specific neuropsychological tests. 
The presence of the metabolic syndrome increased the risk for poor memory during a 12-
year follow-up period among elderly women. Of the single risk factors, only a low level of 
high density lipoprotein cholesterol was significantly associated with the risk of having a 
poor memory. Carotid intima-media thickness predicted an increased risk for poor memory 
and reduced cognitive speed and increased high sensitivity C-reactive protein predicted 
poor memory. No associations were seen between these atherosclerotic risk factors and 
global cognitive function as assessed by the Mini-Mental State Examination. A decreased 
brain-derived neurotrophic factor level was associated with impaired cognitive function in 
ageing women, but not in men.  
These studies highlight the role of modifiable risk factors in the development of cognitive 
impairment and give additional support to current efforts of health care professionals to 
promote in the prevention and treatment of metabolic and cardiovascular disorders. In the 
future, high priority should be given to randomized controlled trials to reveal the impact of 
the risk factor modification on cognition and eventually dementia. 
National Library of Medicine Classification: QU 95, WD 200.5.H8, WD 210, WG 550, WG 
595.C2, WL 104, WL 141, WM 145.5.N4, WM 173.7, WT 104, WT 150 
Medical Subject Headings: Aged; Aging; Atherosclerosis; Brain-Derived Neurotrophic 
Factor; Carotid Arteries; Cholesterol; Cognition; Cognition Disorders; C-Reactive Protein; 
Female; Follow-Up Studies; Geriatric Assessment; Humans; Inflammation; Insulin 
Resistance; Male; Memory Disorders; Metabolic Syndrome X; Neuropsychological Tests; 
Obesity; Population Surveillance; Risk Factors 
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1 INTRODUCTION 
Cognitive impairment, dementia, cardiovascular diseases and type 2 diabetes are 
emerging public health problems. During the next 50 years, the number of individuals 
with dementia is expected to display an approximately fourfold increase (1,2). Mild 
cognitive impairment (MCI) refers to a transitional, high risk state for dementia. In 
population-based studies, the prevalence of MCI is approximately 3% (3,4), though 
values as high as 19% have been reported (5). A recent review indicated that in 
individuals older than 65 years, the mean annual conversion rate from MCI to dementia 
is approximately 10% and this is higher in clinic-based studies (15%) compared to 
population-based studies (7.5%) (6). Poor performance on neuropsychological tests 
occurs several years before clinical diagnosis of dementia (7), and the 
neurodegenerative changes begin well before the clinical manifestations of dementia 
become apparent (8).  
   Recent studies have indicated that MCI and dementia share many risk factors with 
atherosclerotic cardiovascular disease and metabolic syndrome. The main proposed risk 
factors for cognitive impairment and dementia are presented in Figure 1. Importantly, 
many of them are potentially modifiable. However, the follow-up times in many of the 
previous studies have been relatively short, and the measurements for cognitive 
functioning have often not been detailed. Furthermore, there is still controversy about 
how cognitive impairment can be best assessed and defined, nor is there clear consensus 
about which screening instruments are best in the assessment of MCI.  
   While the roles of separate factors of metabolic syndrome have been recently studied, 
little is known about the role of metabolic syndrome in the development of cognitive 
impairment. Currently, very few data are available on cardiovascular status indicators 
possibly mediating the impact of an unhealthy lifestyle on cognition. The aim of the 
present thesis was to evaluate associations between vascular and neuroprotective status 
indicators with regard to the risk of cognitive impairment in ageing men and women. 
The associations between metabolic syndrome, atherosclerosis, inflammation and 
cognitive function were studied using specific tests for cognitive function in a 12-year 
16
follow-up study in elderly women. Finally, the association of a neurotrophic factor with 
cognitive function was assessed in a representative sample of ageing men and women. 
17
Ageing
Physical inactivity 
Unhealthy nutrition 
Inappropriate alcohol 
consumption  Poor fetal conditions 
Genetic predisposition Smoking  
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Social inactivity 
Mental inactivity 
Figure 1. Proposed risk factors for cognitive impairment and dementia.  
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High total cholesterol 
Low HDL cholesterol 
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2 REVIEW OF LITERATURE 
2.1 Cognitive function
2.1.1 Assessment of cognitive function
The memory system is complex and it requires the participation of many interconnected 
brain areas and nerve systems. It is known that several cognitive domains decline in 
ageing, but there is still a lack of normative data concerning cognitive decline in 
specific cognitive domains in ageing. Furthermore, the fact that same cognitive domains 
appear to be implicated in normal ageing and in early Alzheimer's disease (AD) 
suggests that the cognitive deficits observed preclinically are more quantitative, rather 
than qualitative. The schematic view of cognitive transition from normal cognition to 
MCI and to dementia is presented in Figure 2 (8). 
Poor performance on standard neuropsychological tests such as memory and 
executive functions indicate a risk of progression to dementia (7-9). Traditionally, the 
Mini-Mental State Examination (MMSE) (10) has been used in screening global 
cognitive function. MMSE includes aspects of orientation, language, memory, 
concentration and constructional praxis, but is not sensitive enough to measure specific 
cognitive domains. In the detailed assessment of cognitive function, numerous of 
neuropsychological tests have been used to test memory and executive function which 
includes cognitive speed and language (11-14). Further test batteries, such as the 
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 
neuropsychological test battery (15), designed to assess basic cognitive functions 
affected in AD, are appropriate if one wishes to test memory, language, praxis and 
general intellectual status. 
19
Normal Dementia    MCI 
Cognitive function Time
Pathological load 
Figure 2. Schematic view of cognitive transition from normal cognitive function to mild 
cognitive impairment (MCI) and dementia in terms of cognitive performance and pathological 
burden (adapted from Nestor et al. 2004) (8). 
2.1.2 Definition of cognitive impairment and dementia 
During the past years, several terms such as cognitively impaired not demented, possible
dementia prodrome, age-associated memory impairment and age-associated cognitive 
impairment have been used to describe a phenomenon between normal ageing and 
mildly impaired cognitive function (16,17). The term "mild cognitive impairment" is 
generally used as a pathological condition to define persons in a transitional state 
between normal cognitive function and clinically probable AD (Figure 2) (7,17-19). 
Despite the rather wide variety in the concepts used to describe cognitive dysfunction 
(17), the terms have been recently refined to correspond more closely to MCI (3). 
The recommendations for general MCI criteria are represented such that the person 
who is judged to be not normal but does not fulfil the criteria of dementia. Cognitive 
decline should be 1) self-reported and/or if possible, 2) reported by a close relative or 
friend, and 3) objective cognitive measures should be performed, and/or 4) evidence of 
20
cognitive decline based on objective neuropsychological tests. The person with MCI has 
no notable difficulties in activities of daily living (18). Various clinical subtypes of MCI 
have been proposed, are suggested to represent different etiologies and to be risk states 
for different dementing disorders. The subtypes are: a) amnestic MCI; amnestic MCI -
single domain and amnestic MCI -multiple domain, b) non-amnestic MCI; non-
amnestic MCI -single domain and non-amnestic MCI -multiple domain (Figure 3) (17).  
Although there are no generally accepted instruments to define the transition from 
normal cognitive function to MCI, commonly used neuropsychological tests and test 
batteries are recommended. In addition to specific neuropsychological tests, it is 
necessary to incorporate clinical features, combinations of measures, biomarkers and 
neuroimaging for a diagnostic accuracy as well as structured measurements of 
functional capacity (7,17-19). Abnormalities in cerebrospinal fluid biomarkers are 
useful in the prediction and diagnosis of early AD (20,21). Atrophy in mediotemporal 
lobe is suggested to be a significant predictor of conversion from normal ageing to MCI 
(22) as well as progression to AD (23) detected by magnetic resonance imaging. 
Magnetic resonance images of the hippocampus in ageing, MCI and AD are presented 
in Figure 4. The density of grey matter in individuals with MCI and AD can be 
registered by voxel-based morphometry imaging (Figure 5). Functional brain imaging 
offers potential insight into pathological features such as hypometabolism or 
hyperperfusion in MCI and AD (8). However, autopsy studies have revealed that many 
people with neuropathological changes of degenerative or vascular origin have no 
clinical signs of dementia, suggesting that the association between neuropatholgical 
lesions and clinical syndromes is more complex than previously thought. (24). More 
research is needed to clarify the added values of various clinical investigations in the 
diagnostic process. 
   The prevailing definitions of AD or dementia are based on the criteria of Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (25) and the 
National Institute of Neurological Disorders and Stroke-Alzheimer's Disease and 
Related Disorders (NINCDS-ADRDA) (26) working group. The essential features 
included in the DSM-IV are memory impairment and impairment in at least one 
additional cognitive domain, both of which interfere with social function or activities of 
21
daily living. The NINCDS-ADRDA criteria for AD require that the diagnosis should be 
restricted to persons who have 1) clear evidence of progressive and significant 
deterioration of memory and other cognitive domains, 2) onset of the disease is 
insidious, typically after age 65 years and 3) lack of systemic or brain diseases that 
could account for the progressive memory and other cognitive deficits. In addition, the 
presence of psychiatric disorders must be excluded. Techniques to image 
neuropathological characteristics (Figures 4 and 5) and methods to detect pathological 
features e.g. in cerebrospinal fluid increase accuracy in definition of AD even in 
prodromal and preclinical phase (19). 
Vascular cognitive impairment refers to individuals who have all types of mild to 
severe cognitive impairment associated with or presumed to be caused by 
cerebrovascular disease (27). Vascular dementia has been defined by the diagnostic 
criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (25), 
codes of International Classification of Diseases (ICD) (28) and specific criteria for 
ischaemic vascular dementia (29), probable and possible vascular dementia (30), and 
subcortical vascular dementia (31). The proposed criteria for vascular dementia are not 
interchangeable and the sensitivity and specifity of these diagnostic criteria are variable 
(32-34). Vascular cognitive impairment encompasses a heterogeneous group of 
disorders (Table 1). However, none of these criteria sets have been satisfactorily 
validated by prospective studies (27). 
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NYU 1999
Figure 5. Loss of grey matter in 
individuals with mild cognitive 
impairment (red) and Alzheimer's 
disease (blue) using computational 
neuroanatomy method, voxel-based 
morphometry (adapted from Nestor et 
al. 2004, permission by P.S.) (8).
Figure 4. Magnetic resonance 
images of the hippocampus in 
ageing, mild cognitive impairment 
(MCI) and Alzheimer's disease (AD) 
(permission by M. de Leon, New 
York University School of Medicine, 
USA).
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Table 1. Concept of sporadic vascular cognitive impairment according to different 
vascular pathologies (27) 
Type of vascular cognitive 
impairment  
Characteristics 
Multi-infarct dementia Multiple large cortical infarcts are required in developing 
dementia.  
Not very common type in the elderly. 
Post stroke dementia Heterogeneity of the underlying vascular pathology is 
suggested, resulting from different vascular causes and 
changes in the brain, and degenerative pathology. 
Includes patients with multiple corticosubcortical infarcts, 
strategic infarcts, subcortical ischaemic vascular dementia 
and Alzheimer’s disease. 
Develops in up to a third of patients within a year of stroke. 
Is strongly associated with advancing age. 
Subcortical ischaemic vascular 
dementia 
Generally predictable outcome of vascular dementia, which 
incorporates small-vessel disease as the main vascular cause 
with lacunar infarct and ischaemic white-matter lesions as 
the primary type of brain lesion. 
The primary location of lesions is subcortical, and 
subcortical syndrome is the primary clinical manifestation. 
The onset is frequently insidious, and temporal relations 
between the cognitive syndrome, brain imaging features and 
evidence of cerebrovascular disease may not be clear.  
Subcortical ischaemic vascular 
disease without dementia 
White-matter lesions are observed on magnetic resonance 
imaging brain scans.  
The lesions can occur as early as 30 years of age, but their 
prevalence rises strikingly with age, by 70 years of age at 
least 70% of the population is affected. 
Lesions occur in the context of well-recognised vascular risk 
factors as well as novel and poorly recognised risk factors 
for white-matter lesions such as oxidative stress. 
Mixed Alzheimer’s disease 
with cerebrovascular disease 
Vascular and degenerative pathologies interact in terms of 
clinical expression of cognitive impairment. 
No clinical criteria for the diagnosis of Alzheimer’s disease 
with cerebrovascular disease are currently available.  
Is underestimated as a common cause of dementia, 
particularly in elderly people. 
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2.1.3 Epidemiology of cognitive impairment  
The etiology of MCI, vascular dementia, and AD is heterogeneous and still partly 
unspecified. Cognitive impairment, dementia and its subtypes can be defined in various 
ways resulting in varying incidence and prevalence numbers in different studies. In 
population-based studies, the prevalence of MCI has ranged from 1% to 3%, even up to 
19% (3-5) in individuals older than 65 years. In clinical studies, the annual rate of 
conversion from MCI to dementia ranges approximately 10% to 20% (35-37), but this 
number is lower in population-based studies (approximately 7.5%) (6). The incidence of 
MCI is estimated to be from 8 to 58 new patients (4,38,39) per thousand persons 
annually. The prevalence (40) and incidence (41) of dementia and AD increase with age 
and seem to be somewhat higher in women. The number of individuals with dementia is 
expected to increase nearly fourfold by the year 2050 (1,2).
MCI increases the risk of mortality by about 1.5 -fold to 3.0 -fold compared to those 
with normal cognitive function (37,42-44). In a Scandinavian cohort of very old 
individuals, the risk of mortality which resulted from dementia was approximately 30% 
for men and 50% for women (45). 
2.1.4 Pathophysiology of cognitive impairment and dementia  
AD and vascular dementia are two most common dementing diseases. AD is a 
progressive neurodegenerative disorder, characterized by neuronal loss, neuronal 
plaques and neurofibrillary tangles and decreased blood perfusion and metabolism in 
the brain. Hippocampus and entorhinal cortex are the first brain areas to be affected in 
the progressive neurodegenerative process leading to AD (Figure 6) (8). AD may be 
associated with large vessel atherosclerosis and amyloid angiopathy (46). Vascular 
amyloid angiopathy can cause cognitive impairment independent of plaque and tangle 
pathology (47), although its precise role in cognitive function is unclear. Histological
evidence of senile plaque and neurofibrillary tangle formation can be seen in temporal 
lobe up to 40-50 years before the onset of dementia (48). Senile plaques are 
extracellular deposits, predominantly of beta-amyloid. Neurofibrillary tangles are 
intraneuronal inclusions, which are, in part, composed of abnormally phosphorylated 
tau protein (49).
26
   After ischemic stroke, dementia may occur in as many as one out of four elderly 
individuals within a short term (50). Furthermore, the presence of silent brain infarcts, 
common even in healthy elderly people, is suggested to more than double the risk of 
dementia (51).  
   The definition of vascular dementia has been historically based on stroke and multi-
infarct model and required memory impairment as an essential feature (27). However, 
executive dysfunction seems to be a typical cognitive disorder with a vascular 
foundation (52). Furthermore, mixed pathology is reported to be common; in AD there 
is evidence of considerable cerebrovascular pathology, including small-vessel disease 
and microinfarction, and there is evidence for substantial overlap between vascular 
dementia and AD (Table 1) (27). About half of patients with vascular cognitive 
impairment exhibit dementia (53).
Other dementias such as Lewy body dementia and frontal lobe dementia are more 
uncommon and exhibit somewhat dissimilar characteristics than that encountered with 
vascular dementia and AD (54). Moreover, there are rare causes of dementia (e.g. 
traumatic and infectious), which will not be referred to in the present thesis. 
   Ageing predisposes an individual to atherosclerosis and its consequences (55). 
Increased oxidative stress and accumulation of oxidatively modified molecules such as 
proteins, nucleic acids and lipids, promote dysfunction of various metabolic and 
signalling pathways (56). In addition, energy deficits may occur in brain neurons due to 
an alteration in the cerebral vascular function. In unsuccessful brain ageing, molecular 
damage to neurons and inflammatory processes result in synaptic dysfunction and 
neuronal degeneration and death, without replacement of the lost neurons (56). In 
successful brain ageing, the neurons and glial cells adapt to the adversities of ageing by 
increasing their ability to cope with stress, and by compensating for lost or damaged 
cells by producing new brain cells and remodelling neuronal circuits (56). One possible 
explanation may be related to neurotrophic factors.
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Figure 6. Hippocampus and entorhinal cortex 
are the first brain areas to be affected in a 
progressive neurodegenerative process in 
Alzheimer's disease (permission by M. de 
Leon, New York University School of 
Medicine, USA).
2.2 Risk factors for cognitive impairment 
2.2.1 Hypertension
There is increasingly strong evidence that hypertension is a risk factor for cognitive 
impairment and dementia. Elevated blood pressure at midlife increases the risk of 
dementia and its main subtypes, AD and vascular dementia (57-59) and cognitive 
impairment (60-62) later in life. Increased blood pressure at midlife has been associated 
with brain atrophy and increased number of neuritec plaques in neocortex and 
hippocampus, as well as with increased number of neurofibrillary tangles in 
hippocampus at death in elderly men (63).  
   Even high blood pressure in old age has been reported to increase the risk of 
subsequent dementia/AD (64). However, results from studies where the blood pressure 
measurement was conducted later in life and/or with shorter follow-up times, have 
yielded inconsistent results (65). The divergent findings may be explained due to the 
timing of blood pressure measurement in relationship to age and the clinical onset of 
cognitive impairment (66). Blood pressure may become decreased many years before 
the diagnosis of dementia and be a part of the disease process (64,65). 
Systolic blood pressure and pulse pressure increase with age mainly due to reduced 
elasticity of the large arteries. Atherosclerosis results from structural abnormalities in 
arteries, and together with endothelial dysfunction, leads to arterial rigidity, which in 
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turn increases systolic blood pressure (67). High blood pressure is a major risk factor for 
stroke and white-matter lesions, which in turn may promote the clinical expression of 
AD and dementia (65). Thus, atherosclerosis may be involved in the pathogenesis and 
progression of both vascular dementia and AD (65). There is increasing evidence from 
epidemiological and randomized trials that antihypertensive treatment may prevent 
cognitive impairment and dementia (65). 
2.2.2 Lipids and lipoproteins
Midlife high serum total cholesterol level was associated with MCI (60) and AD in the 
elderly in population-based studies (57,59). In an autopsy study, the premortem 
presence of hypercholesterolemia has been shown to be an early risk factor for AD 
amyloid pathology in human brain (68). Similarly for blood pressure, studies with 
shorter follow-up times or where the cholesterol measurements have been conducted 
later in life, have reported no association (69,70) or a negative association between 
cholesterol and risk of dementia (71). It has been reported that cholesterol values may 
start to decline a decade before the clinical diagnoses of dementia and may be a part of 
the AD process (72,73). The exact mechanisms relating cholesterol to AD are not 
known, but aberrations of cholesterol homeostasis have been linked with the amyloid 
precursor protein metabolism, beta-amyloid production (74) and several other features 
of AD pathology such as phosphorylation of tau protein and the production of 
neurofibrillary tangles (74).
   There is little data available on the association between low density lipoprotein (LDL) 
cholesterol and high density lipoprotein (HDL) cholesterol and cognitive function 
(69,75). A low level of HDL cholesterol was associated with cognitive impairment and 
dementia (76-78), but inconsistent findings exist (79). HDL cholesterol is critical for the 
maturation of synapses and the maintenance of synaptic plasticity (80,81), and high 
HDL cholesterol levels may protect against hippocampus atrophy in elderly people (82), 
as well as preventing inflammation (83) and the aggregation and polymerization of beta-
amyloid protein (84). A low level of HDL cholesterol is a known risk factor for 
atherosclerosis (85), which in turn may lead to impaired cognitive function. In the 
follow-up studies, plasma triglycerides have either not been associated with cognitive 
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performance (69,86), and dementia (71) or else the association has been weak (87). 
Epidemiological studies with different study designs and populations have shown a 40-
70% reduction in the risk of AD associated with statin use (88-90). On the other hand, 
in two randomized placebo-controlled trials, no benefits for statin use against cognitive 
decline were found (91,92). 
2.2.3 Overweight and obesity
Obesity at midlife has been associated with an increased risk of dementia and AD in 
later life (93,94). Overweight among elderly women has also reported to be predictive 
for subsequent AD (95). In an exercise and diet intervention study, loss of intra-
abdominal fat was associated with improved memory in ageing people who were at an 
increased risk for developing type 2 diabetes (96). On the other hand, weight loss in late 
life is suggested to precede a clinical diagnosis of dementia (97,98). There is little data 
available about the association between obesity and MCI. Since it is a risk factor for 
cardiovascular disease, obesity may have an indirect effect on cognitive function. 
Adipose tissue releases cytokines and many bioactive mediators, such as leptin, 
adiponectin, interleukin-6 and tumor necrosis factor-alpha, that influence body weight 
homeostasis, insulin resistance, diabetes, alteration in lipids, blood pressure, blood 
coagulation, fibrinolysis and inflammation and leads to endothelial dysfunction and 
atherosclerosis (99), which in turn is associated with cognitive function. 
2.2.4 Glucose intolerance  
Glucose intolerance and type 1 and type 2 diabetes have been linked with cognitive 
impairment (100). In prospective studies, the presence of diabetes has increased the risk 
for cognitive impairment (101-103), and dementia (104,105). These associations have 
been found also in cross-sectional studies (106-108). There is less data available on the 
association between pre-diabetic conditions including impaired fasting glucose (IFG) 
and impaired glucose tolerance (IGT) and cognitive function. In follow-up studies, IGT 
associated with mildly impaired cognitive function in men and women (109) stroke-
related dementia in men (110), and AD (106) or such an association was not found 
(111).
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There are several plausible mechanisms which could mediate the association between 
diabetes, cognitive impairment and dementia (Figure 7). Acute and chronic 
hyperinsulinemia have opposite effects on the neural substrate of memory: acute 
hyperinsulinemia may facilitate memory whereas chronic hyperinsulinemia and insulin 
resistance are to be deleterious to memory (112). Hyperinsulinemia and insulin 
resistance are well established risk factors for vascular diseases which in turn have 
implications for vascular dementia and AD (112). Insulin receptors are distributed 
unevenly throughout the brain, being present on synapses and modulating 
neurotransmitter function (113). The overlapping distributions of insulin receptors, 
insulin and insulin-sensitive glucose transporters are consistent with the possibility of 
insulin-stimulated glucose uptake in specific brain regions, such as the hippocampus 
and hypothalamus (113). Alterations in insulin metabolism have effects on central 
nervous system, through their involvement in synaptic plasticity and amyloid and tau 
metabolism (100). Moderate hyperinsulinemia can elevate inflammatory markers and 
beta-amyloid concentration in the brain, and may increase the risk for AD (114). Type 2 
diabetes is associated with atrophy in hippocampus (115), and is a risk factor for silent 
and symptomatic brain infarcts (100,116,117), and in these ways it can lead to cognitive 
impairment. 
2.2.5 Metabolic syndrome  
The metabolic syndrome is characterized by the clustering of obesity, glucose 
intolerance, hypertension, low HDL cholesterol level, and high triglycerides, each of 
which is a known risk factor for atherosclerotic cardiovascular events (85). The 
pathophysiological feature is insulin resistance (118), which in turn is associated with 
obesity (119). Obesity may induce systemic oxidative stress and increased oxidative 
stress is, at least partly, the underlying cause of dysregulation of adipocytokines and 
development of metabolic syndrome (119). Obesity as well as hypertension and type 2 
diabetes have been suggested to be essential in the pathogenesis of vascular dementia 
and AD (57,64,104,112). In the diabetic condition, oxidative stress impairs glucose 
uptake in muscle and fat (120,121) and decreases insulin secretion from pancreatic beta 
cells (122). Increased oxidative stress also underpins the pathophysiology of 
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hypertension (67) and atherosclerosis (123) and affects directly the condition of 
vascular wall cells. In a 1-year randomized controlled trial, weight loss reduced 
metabolic syndrome in middle-aged men and women (124).  
   In prospective studies, the association between the clustering of vascular risk factors 
and dementia was found in men (125), with AD in women (78) and cognitive 
impairment in men and women, especially in those with a high level of inflammation 
(126). Metabolic syndrome also has been associated with dementia and cognitive 
impairment in cross-sectional studies (127-129). However, in very old age the presence 
of the metabolic syndrome was associated with decelerated cognitive decline (130). The 
current data are limited, because the measurements used to assess cognitive function 
were non-specific, especially for MCI, populations were heterogeneous and definitions 
of metabolic syndrome have been inconsistent. 
SusceptibilityPhysical inactivity 
genesUnhealthy nutrition 
Figure 7. Suggested pathogenesis of cognitive impairment in metabolic syndrome and type 2 
diabetes (modified from Biessels 2005) (131). 
Alzheimer type 
pathology 
Metabolic syndrome 
Insulin resistance 
Type 2 diabetes Ischemic cerebro- 
vascular disease 
Cognitive impairment
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2.2.6 Atherosclerosis  
In the elderly, there is cumulative evidence pointing to a link between vascular risk 
factors and atherosclerosis and AD (132,133). Some investigators have proposed that 
AD occurs as a secondary event related to atherosclerosis of extracranial (134) or 
intracranial (135) vessels and is linked to brain hypoperfusion (136) or discrete brain 
infarction (137). One tenable hypothesis is that atherosclerosis and AD are independent, 
but convergent disease processes (132). The earliest atherosclerotic changes include
increased endothelial permeability to lipoproteins and this is suggested to precede the 
formation of atherosclerotic lesions (138). Little data is available on the association 
between endothelial dysfunction and cognitive function (139). 
Several epidemiological studies suggest that cardiovascular and cerebrovascular 
diseases are associated with the subsequent development of AD (137,140). Vascular 
damage in the brain may create the kind of conditions, possibly due to inflammation, 
which predispose to neurodegeneration (75). On the other hand, inflammatory processes 
increase the presence of vascular injury, such as those caused by hypertension, 
atherosclerosis and hypercholesterolemia (141,142). Alternatively, cerebrovascular 
disease may simply increase the severity of dementia or hasten the age at onset 
(75,117,143). Atherosclerosis is suggested to be a progressive disease which acts 
throughout the lifespan and which is characterized by the accumulation of lipids within 
arterial walls. Specific arterial sites such as bifurcations, are prone to local plaque 
formation (138). 
The role of peripheral atherosclerosis, which can be quantitated by high resolution B-
mode carotid artery ultrasonography as intima-media thickness (IMT), as a detrimental 
factor for cognitive function is still unclear. The few longitudinal studies that have 
evaluated the association between carotid IMT and cognitive function have yielded 
conflicting results (144-146). Some cross-sectional studies have found an inverse 
association between carotid IMT, and global cognitive function (147) as well as 
memory (148,149) and executive function (144). An association has been found 
between the increasing prevalence of plaques in the carotid arteries and poor 
performance on various neuropsychological tests in men, though not in women (150). 
Carotid IMT and plaques may represent partly different ethiopathological conditions 
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and different phases of the atherosclerotic process (151), and thus, the effects on 
cognition may differ. 
Microglial activation is suggested to be an early event in the pathogenesis of AD in 
individuals with mild and early disease (152). Immunohistochemical analysis of 
advanced carotid atherosclerotic plaques has revealed the presence of amyloid precursor 
protein, beta-amyloid, platelets and activated macrophages that surround intimal 
microvessels (153). Furthermore, pathological angiogenesis is hypothesized to have a 
role in the pathogenesis of AD (154). Abnormalities in the brain microcirculation in AD 
have been detected, and it has been suggested that these precede the parenchymal 
amyloid deposit, and further promote the development of neurodegenerative diseases 
(155,156).
2.2.7 Inflammation
The serum level of high sensitivity C-reactive protein (hsCRP) is a marker of systemic 
low-grade inflammation, and is associated with increased risk of stroke (133) and 
cardiovascular disease (157). The inflammatory response may contribute to neuronal 
dysfunction, and ultimately lead to neuronal death, although the precise sequence of 
events is unclear. Inflammatory markers such as interleukin-1, interleukin-6, tumor 
necrosis factor -alpha and hsCRP have been suggested to be involved in the 
pathogenesis of AD (133,158-160), and other types of dementia (161), and to be an 
early hallmark in the AD pathogenesis {{449 Tarkowski,E. 2003; }}. Limited data of 
the role of inflammatory biomarkers in MCI are available (18).
Increased serum or plasma concentrations of hsCRP has been associated with 
impaired cognition (164-166) and an increased risk of vascular dementia (167) and AD 
in follow-up studies (168-170) though other studies have failed to confirm these 
associations (171,172). Elevated serum levels of hsCRP were associated with an 
increased incidence of AD in the subsequent 25 years, independent of cardiovascular 
risk factors (169). In large cross-sectional studies, hsCRP associated positively with 
measures of adiposity such as body mass index (BMI), waist circumference and waist-
to-hip ratio (173,174), which in turn may have an effect on neuronal degeneration 
(126,165,169). Weight loss may be one way to lower elevated hsCRP levels (175). 
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2.2.8 Physical inactivity
There is some evidence, based on follow-up studies, that regular physical activity has a 
protective effect against cognitive impairment (176-178) and dementia (94,179,180), 
and poor cardiorespiratory fitness precedes the cognitive decline (181). In a 1-year 
randomized controlled trial, persons with AD undertook a simple exercise program, and 
had a slower decline in daily activities than those with AD and routine medical care 
(182). Physical activity makes a beneficial contribution to vascular and metabolic risk 
factors (99,183-189) and atherosclerotic cardiovascular disease (190,191), which in turn 
may have a crucial role in the prevention and treatment of cognitive impairment and 
cognitive decline.
2.2.9 Unhealthy nutrition 
In follow-up studies, unsaturated fat intake at midlife protected against the risk for 
cognitive decline, whereas a moderate intake of saturated fats increased the risk (192). 
A Mediterranean diet had a beneficial effect on cardiovascular risk factors (193) and 
was associated with a reduced risk for AD (194). In the meta-analyses, fish 
consumption (195) and fruit and vegetable consumption (196) have had a protective 
effect on ischemic (195,196) and haemorrhagic (196) stroke. However, a systematic 
review suggested that, the results were inconclusive with respect to vitamin B6, or B12 or 
folic acid supplementation, alone or in combination as a means of maintaining cognitive 
function (197). Caffeine may stimulate the secretion of acetylcholine, which in turn 
prevents beta-amyloid-induced neurotoxicity in cerebellar neurons (198), or may 
increase the antioxidant capacity in plasma. There is limited data about the effects of 
dietary modifications and cognitive function. 
2.2.10 Inappropriate alcohol consumption
Increasing alcohol consumption has been associated with unfavourable metabolic 
abnormalities such as increased blood pressure, uric acid and mean fasting glucose 
(199). Long-term heavy alcohol drinking (200) or binge drinking, consumption of a 
large amount of alcohol in one session (201), has been suggested to lead to dementia. 
On the contrary, moderate alcohol drinking in middle-age and old age was favourably 
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related to cognitive function in several cognitive domains in late-life (202) and it 
appears to decrease the risk of MCI approximately twofold compared to never drinkers 
(203). Further, patients with MCI who were moderate drinkers had a lower rate of 
progression to dementia than the non-drinkers (204). No associations were found 
between any levels of drinking and the incidence of MCI (204). Mild to moderate use of 
alcohol may decrease the risk for dementia/ AD compared to non-use of alcohol (205). 
Alcohol by itself may have favourable effects on HDL cholesterol level, antioxidant 
activity, nitric oxide production, endothelial function and platelet aggregation (207). 
More research is needed to clarify the association between the consequences of alcohol 
consumption and cognitive function. 
2.2.11 Smoking 
Smoking may increase the risk for cognitive impairment and dementia (208-211) 
compared to never-smoking. Some earlier case-control studies did suggest that smoking 
may be protective for AD, but this may have been biased by a "healthy survivor" effect 
(212). In voxel-based morphometry, decreased regional gray matter density has been 
determined in smokers compared to never-smokers (213). Furthermore, smoking is 
associated with an increased incidence of cardiovascular disease including coronary 
heart disease and cerebrovascular disease, elevated oxidative stress (212), and all of 
these would be predicted to impair cognitive function. 
2.2.12 Hormonal changes 
Several epidemiological studies have suggested that women using hormonal replacing 
therapy have a lower risk of cognitive impairment and dementia (214). However, 
randomized controlled trials have not verified these results (215). In a meta-analysis, the 
use of hormone replacement therapy failed to protect against coronary heart disease 
(216). There is little data available on the association between hormonal changes and 
cognitive function in men (217). 
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2.2.13 Socioeconomic and psychosocial risk factors 
The association between education and lower risk of dementia has been reported in 
several studies. Higher levels of education seem to protect against cognition impairment 
and delay the clinical manifestation of dementia (218). In addition to physical activity, 
other leisure-time activities like social activities and mental stimulation in the elderly 
may also protect against dementia (219,220). These leisure-time activities are often 
interrelated and being socially active may encourage an individual to be also physically 
active (221). Education and leisure activities may be important in increasing cognitive 
reserve, and thereby in the maintenance of cognitive function and the prevention of a 
cognitive decline (222,223). Depressive symptoms may associate with a pre-clinical 
phase of AD, but the causal relation with AD is controversial (224). In patients with 
MCI, depression has increased the risk of developing AD (225). On the other hand, 
psychosocial factors (226), socio-economic inequalities (227) and depression (228) are 
suggested to be associated with cardiovascular risk factors and diseases, and that kind of 
interaction may strengthen the link to cognitive impairment.  
2.2.14 Genetic risk factors
Human apolipoprotein E (APOE) has three alleles (H2, H3, H4), with the APOE H4 allele 
representing a major genetic risk factor for AD (229,230). The mechanisms relating 
APOE H4 allele to AD are still partly unknown. APOE is an important cholesterol 
transporter, and it has been found in extracellular amyloid deposits and intracellular 
neurofibrillary tangles in the brain. The APOE H4 allele is known to strengthen all of the 
biochemical disturbances which are characteristics of AD, such as beta amyloid 
deposition, tangle formation, neuronal death, oxidative stress, synaptic plasticity and 
dysfunction of lipid homeostasis and cholinergic signalling (231). In contrast, the APOE 
H2 allele may be protective (233). In the meta-analysis, a role for the APOE genotype in 
the pathogenesis of some cases of ischemic cardiovascular disease has been postulated 
(232). In the meta-analysis, a role for the APO-E genotype in the pathogenesis of some 
cases of ischemic cardiovascular disease has been postulated (233). Also several other 
risk genes for cognitive impairment and AD have been suggested (234), but their impact 
and role need still to be verified.
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2.2.15 Reduced neuroprotective function 
The mechanisms that maintain the integrity of nerve cell circuits and facilitate responses 
to environmental demands include the production of neurotrophic factors (56,235,236). 
Brain-derived neurotrophic factor (BDNF), a member of the neurotrophins's 
superfamily, modulates synaptic transmission and plasticity and has a key role in 
regulating growth, survival, and maintenance of neurons (236-240). BDNF and its 
receptor tropomyosin-related kinase B (TrkB) are expressed at high levels in 
hippocampus (236,241), an area that is crucial in memory, learning (242) and the 
development of AD (8). 
   While circulating concentrations of BDNF (243,244) and its receptor TrkB (245,246) 
has decreased, hippocampal BDNF mRNA levels have remained unchanged with 
increasing age (245,246). Low circulating (247,248) and post-mortem parietal cortex 
levels of BDNF have been found in patients with MCI (249) and AD (249-251). 
Furthermore, low BDNF levels have been observed in individuals with type 2 diabetes, 
(252) the metabolic syndrome, (253) acute coronary syndromes, (254) depression (255) 
and with physical inactivity, (256-258) all of which have been linked with cognitive 
impairment and AD (94,104,132). 
   There is little data available on the link between circulating BDNF and MCI (249) and 
AD (248,250,251,259) in humans. No data are available of the association between 
decreased BDNF and cognitive function in general population. 
2.3 Summary of the review of literature 
As more and more individuals reach advanced age, the occurrence of cognitive 
impairment and dementia will increase substantially. There were approximately 25 
million individuals with dementia in 2000, and by the year 2050, this number is 
estimated to increase to over 110 million. Dementia seems to be more common in 
females; this is partly because of females have a longer life expectance than men, but 
also other factors (e.g. hormonal, lifestyle-related) may be involved. Evidence has been 
accumulating during the recent years indicating that cognitive impairment and dementia 
share many risk factors with cardiovascular disease. However, there is still a lack of 
data which would clarify the role of vascular risk factors in the development of 
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cognitive impairment and the mechanisms underlying these associations. Obesity and 
other cardiovascular risk factors are suggested to be interrelated with lifestyle factors 
such as physical activity, fitness and nutrition, and thereby with cognition, but the data 
are limited. Representative long-term studies examining several biological and lifestyle-
related risk factors and having data on various cognitive domains are needed to better 
understand these associations and to identify those individuals who are potentially at 
increased risk for dementia. Furthermore, randomized controlled trials are required to 
investigate to what extent risk factor modification can effect cognitive functioning. 
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3 AIMS OF THE STUDY 
The aim of the present thesis was to evaluate associations between vascular and 
neuroprotective status indicators with regard to the risk of cognitive impairment in 
ageing men and women. The associations between metabolic syndrome, atherosclerosis, 
inflammation and cognitive function were studied using specific tests for cognitive 
function in a 12-year follow-up study in elderly women. The association of a 
neurotrophic factor with cognitive function was assessed in a representative sample of 
ageing men and women.  
The specific aims of the present study were to investigate: 
1) The association of metabolic syndrome and its major components on cognitive 
function in elderly women in a 12-year follow-up. (Study I) 
2) The association of peripheral atherosclerosis and cognitive function in elderly women 
in a 12-year follow-up. (Study II) 
3) The association between serum high sensitivity C-reactive protein and cognitive 
function in elderly women in a 12-year follow-up. (Study III) 
4) The association between brain-derived neurotrophic factor and cognitive function in 
ageing men and women in a cross-sectional setting. (Study IV)
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4 METHODS 
4.1 Study Population and design 
Studies I-III
The subjects were derived from a population-based, randomly selected sample of 299 
women 50 to 60 years of age, initially examined as part of a large population-based risk 
factor survey, the Finnish part of the WHO MONICA (Monitoring Trends and 
Determinants in Cardiovascular Disease), in 1982 (Figure 8) (260). The original study 
sample was stratified separately for men and women by ten year age groups to obtain 
even age and gender specific groups. The subjects lived in the province of Kuopio, one 
of the monitoring areas of the Finnish part of the WHO MONICA project. For the 
baseline examinations of the present study in 1991-1992, we only evaluated women 60 
to 70 years of age. Of the 260 women who were invited, a total of 202 women 
completed the examinations between October 1991 and March 1992. Because 32 
women had died (n=27) or could not be contacted (n=5), 170 women 70 to 80 years of 
age were available for the 12-year follow-up study in 2003. Of 170 women who were 
invited in the follow-up study, 57 did not participate (Figure 8). All of the 113 women 
who participated in the study completed the examinations between March 2003 and 
June 2003 (Figure 8). After excluding the women with missing data on any variable of 
interest at baseline or after 12 years of follow-up, the final study populations consisted 
of 91-101 women with complete data (Table 2). A detailed evaluation of cognitive 
function was performed in 2003. Otherwise, the same methods were used to assess 
study variables in study years 1991-1992 and 2003. The women who were participated 
in both study years were included in the analysis. The study protocol was approved by 
the Ethics Committee of the University of Kuopio. All participants provided a written 
informed consent. 
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Invited in 1992 
n=260
Home visit (1993)              42 
Lost for follow-up              16
Follow-up in 1992
n=202
Baseline of 
 Studies I-III 
No contact information         5
Death                   27 
Invited in 2003
n=170
Musculoskeletal problems 11
Dementia                    2
Stroke                    1
Cancer                    1
Other health problems       18 
Transportation problems    10
Loss of motivation               8
Other reasons                       2
Death                  4
Follow-up in 2003
n=113
12-year follow-up 
of Studies I-III 
Lost for follow-up               23
Death                    16 
Finmonica in 1982
n=299
Figure 8. Formation of study population in the Studies I-III. 
42
Study IV 
The subjects were participants of the Dose-Responses to Exercise Training (DR’s 
EXTRA) Study, which is an ongoing 4-year randomized controlled trial on the effects 
of regular physical exercise and diet on endothelial function, atherosclerosis and 
cognition (Figure 9). The study population was a representative random sample of 1500 
men and 1500 women 55-74 years of age living in the city of Kuopio in Eastern 
Finland. Of the initially invited individuals, 81 had died, moved elsewhere or had a 
serious chronic disease and therefore were not in a position to participate in the study. 
Furthermore, 210 did not respond to the postal invitation and 647 stated that they were 
not interested participating in the study. Accordingly, 2062 men and women were 
willing to participate in the study and 1410 subjects participated in all four baseline 
examinations between April 2005 and November 2006. Reasons for not participating in 
the visits were cardiovascular disease (n=33), musculoskeletal disease (n=27), cancer 
(n=14), dementia (n=8), other diseases (n=75), death (n=33), removal from Kuopio 
(n=59), loss of motivation (n=207), and unknown reasons (n=196) (Figure 9). After
excluding the subjects with missing data on BDNF (n=16) or cognitive function (n=1) 
and those with type 1 diabetes (n=4), the final study sample consisted of 1389 
individuals (684 men, 705 women). The study protocol was approved by the Ethics 
Committee of the Kuopio University and University Hospital. All participants provided 
a written informed consent.  
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                    n=16 010 
Original subject source of men and women aged 55-74 years in 2002 
Figure 9. Formation of study population in the Study IV. 
Reference Aerobic 
Exercise
Resistance
Exercise
Dietary Aerobic 
+Dietary
                    n=3000 
Resistance
+Dietary
              Random sample, 
   invited to the study in 2002 
                    n=2062
Willing to participate 
                    n=1829 
 Invited to the baseline  
examinations in 2005
                    n=1479  
     Participated in the baseline 
      examinations in 2005-2006
Death                  24 
CVD                 12 
Cancer                 12 
Dementia                   4 
Musculoskeletal disease    15 
Other disease                   29  
Loss of motivation           126 
Moved elsewhere               38 
Unknown reasons              84 
Unreachable                        6
=                    n=1410 
  Randomization  
CVD                 18 
Dementia                   1 
Musculoskeletal disease     8 
Other disease                  19  
Loss of motivation            22 
Moved elsewhere                1 
Run-in phase in 2003-2005 
Death                   9 
CVD                  3 
Cancer                  2 
Dementia                  3 
Musculoskeletal disease    4 
Other disease                 27  
Loss of motivation           59 
Moved elsewhere             20 
Unknown reasons           103 
Unreachable                       3 
Death                                20 
Severe disease                  48 
Moved elsewhere             13 
Not interested                 647 
No response                    210 
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Table 2. Study populations of the Studies I-IV 
Study Study Population 
N
Exposure Outcome 
I Women
101
Metabolic
syndrome 
Risk of poor cognition during 12 years1
II Women
91
Atherosclerosis Risk of poor cognition during 12 years2
III Women
97
Inflammation Risk of poor cognition during 12 years3
IV Men and Women 
1389
Brain-derived
neurotrophic factor 
level
Cognitive function at baseline of the 
DR's EXTRA Study4
1 Metabolic syndrome at baseline and cognitive function at 12-year follow-up,  
2 Carotid intima-media thickness at baseline and cognitive function at 12-year follow-up and  
3 Serum high sensitivity C-reactive protein at baseline and cognitive function at 12-year follow- 
  up in a randomly selected cohort based on the Finnish part of the WHO MONICA in 1982.
4 DR's EXTRA Study; a randomized controlled 4-year trial.
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EXAMINATION PROTOCOL 
Studies I-III
Baseline visits 
Examinations were carried out over four days, at least eight days apart. The examination 
protocol consisted of a wide variety of examinations including bone mineral density, 
functional capacity, global cognitive function, depression, biochemistry, anthropometry, 
carotid atherosclerosis, nutrition, and questionnaires about physical activity, health 
status, lifestyle and demographic factors.  
The study visits and the measurements used in Studies I-III are presented here. The 
women brought the completed questionnaire of background information which has been 
mailed two weeks before the survey to the first visit. A study nurse checked the 
questionnaire at that time. Global cognitive function and depression were assessed. In 
the second visit, the women provided blood samples for laboratory determinations. The 
women were instructed to fast 12 hours before these measurements and to abstain from 
drinking alcohol and using analgesics (except paracetamol) for one week. In the third 
visit, a trained nurse measured carotid artery IMT, body weight and height, waist and 
hip circumference and blood pressure.  
12-year follow-up visits 
Examinations were carried out over two days, at least eight days apart. The examination 
protocol consisted of a wide variety of examinations including functional capacity, 
global and detailed cognitive function, depression, biochemistry, anthropometry, carotid 
atherosclerosis, nutrition, and questionnaires of physical activity, health status, lifestyle 
and demographic factors. The invitation letter contained general information about the 
study. Those who did not respond to the invitation letter were phoned to determine the 
reason for non-participation. 
In the first visit, the women gave blood samples for laboratory determinations. Before 
these measurements the women were instructed to fast for 12 hours and to abstain from 
drinking alcohol, using analgesics (except paracetamol) for one week. At the same visit, 
carotid artery ultrasonography was performed, and a self-administered questionnaire of 
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background information was given to be completed at home. On the second visit, body 
weight and height, waist and hip circumference and blood pressure were measured. 
Cognitive function was assessed using a detailed test battery including a screening test 
of global cognitive function. A nurse received and checked the self-administered 
questionnaire on the background information. 
Study IV
Examinations were carried out over three days, approximately seven days apart. The 
examination protocol consisted of a wide variety of examinations including 
cardiorespiratory fitness, carotid atherosclerosis, endothelial function, muscle and 
adipose biopsy, cognitive function, depression, functional capacity, biochemistry, 
anthropometry, blood pressure, nutrition, and questionnaires about physical activity and 
background information. The invitation letter contained general information of the 
study, instructions about the laboratory measurements and instructions how to complete 
the self-administered questionnaire of background information. Those who did not 
respond to the invitation letter were phoned to determine the reason for non-
participation. 
The study visits and the measurements used in the Study IV were as follows: on the 
first visit, the subjects gave blood samples for laboratory determinations. Before these 
measurements the subjects were instructed to fast for 12 hours and to abstain from 
drinking alcohol for three days, from smoking for 12 hours and from intense physical 
activity for one day. During the same visit, the subjects returned the self-administered 
questionnaire of background information, and anthropometry and blood pressure were 
measured. On the second visit, a cognitive test battery including a depression scale was 
performed, and the questionnaire about background information was checked and 
completed. On the third visit, the randomization into a reference group and five 
intervention groups was performed. After these visits, a 2-hour Oral Glucose Tolerance 
Test (OGTT) was performed in those who met the specific criteria (see 4.6). 
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4.2 Assessment of Cognition 
4.2.1 Studies I-III 
Global cognitive function was assessed by the MMSE score (10) at baseline and at 12-
year follow-up (Table 3). At follow-up, cognitive function was assessed in more detail 
using measures of memory and cognitive speed (Table 3). Memory was assessed using 
the Word Recall Test (261,262) and a prospective memory task (263). Cognitive speed 
was assessed with the first and second chart of the Stroop Test (264) and with the 
Letter-digit Substitution Test (265). 
4.2.2 Study IV 
Cognitive assessments were performed using the CERAD neuropsychological test 
battery (Table 4) (15), which is designed to assess basic cognitive functions such as 
memory, language, praxis and general intellectual status affected in AD. Norms are 
available for the use of CERAD in the Finnish population (266). Trained study nurses 
performed the tests during the second study visit.
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Table 3. Individual cognitive tests carried out in Studies I-III 
Test Object Instruction and score 
Mini-Mental State 
Examination 
To measure global 
cognitive function 
including orientation, 
language, memory, 
concentration and 
constructional praxis. 
The maximum score is 30. 
Word Recall Test To measure immediate 
memory. 
Three different word lists, including 10 
words matched for word frequency are 
presented from tape. The score of 
immediate recall was the total number of 
correct words in three word lists. The 
maximum score is 30. 
Prospective
Memory Task 
To measure prospective 
memory. 
At the beginning of the test session, the 
subject was asked to remind the 
investigator that she must sign a paper at 
the end of the test session. The score was 
categorized as remembering without 
reminder (score=4), with one reminder 
(score=3), with two reminders (score=2) 
or not remembering (score=1). 
Stroop Test To measure cognitive 
speed.
The first and second chart of the 40 item 
Stroop Test using time needed to read 
the normal text for colour names and 
naming of colour dots on a sheet of 
paper. Higher scores indicate poorer 
cognitive speed.  
Letter-digit
Substitution Test 
To measure cognitive 
speed.
The subject is given an example of 
letters and corresponding numbers. The 
subject is asked to copy numbers in 
blank cells below letters as shown in an 
example during 60 seconds. The 
maximum score is number of correctly 
copied numbers during 60 seconds. 
Lower scores indicate poorer cognitive 
speed.
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Table 4. Individual cognitive tests in the order of administration within the CERAD battery  
Test Object Instruction and score 
Verbal Fluency 
Test
To measure semantic 
memory, verbal production 
and language. 
The subjects were asked to name as 
many animals (animal category) as 
possible in 1 minute. The score is the 
total number of different animals named. 
Modified Boston 
Naming Test 
To measure visual naming. The subjects were asked to name 15 
objects. The items are stratified into 
three groups of five items each, the 
names having high, medium, and low 
frequency of occurrence in the Finnish 
language. The maximum score is 15. 
Mini-Mental State 
Examination 
To measure global 
cognitive function 
including orientation, 
language, memory, 
concentration and 
constructional praxis. 
The maximum score is 30. 
Word List Memory To measure ability to 
remember newly learned 
information. 
The subjects are presented with 10 
unrelated items to remember on printed 
cards. The subjects are instructed to read 
aloud each word as it is presented. 
Immediately following presentation of 
each 10 words, the subject is asked to 
recall as many items as possible. On 
each of three learning trials, the 10 
words are presented in a different order. 
The maximum score on each trial is 10. 
The maximum total score is 30. 
Constructional
Praxis
To measure visuo-spatial 
and constructional ability. 
Four line drawings of figures of 
increasing complexity (circle, diamond, 
overlapping rectangles and cube) are 
presented to the subject for copying. At 
the end of the session, the subject is 
asked to make a mental note of the 
objects, because later they will be asked 
to draw them without model. The 
maximum score is 11. For each subject, 
a saving score can be calculated and is 
presented as a percentage reflecting the 
delayed ability to draw the objects 
without model [(copy from 
object/delayed drawing)* 100]. 
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Word List Recall To measure delayed 
memory. 
After 5 minutes for the Word List 
Memory task the subject is asked to 
remind as many words as possible. A 
maximum of 90 seconds is allowed. A 
maximum number of correct responses is 
10. For each subject, a saving score can 
be calculated and is presented as a 
percentage reflecting the relative amount 
of verbal information retained over the 
delay interval [(delayed words/Trial 3 
words from Word list memory)* 100]. 
Word List 
Recognition
To measure correctly 
recognized words presented 
in the Word List Memory 
task.
The words are presented among 10 
distracting words. The number of 
correctly identified distracting words is 
also counted. The maximum score for 
each is 10. 
Clock Drawing To measure executive 
function.
The subject is asked to draw a clock with 
all the numbers, and set the hands at ten 
past eleven. The maximum score is 6. 
CERAD; The Consortium to Establish a Registry for Alzheimer's Disease neuropsychological 
test battery (15). 
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4.3 Assessment of blood pressure 
Blood pressure was recorded using a mercury sphygmomanometer from the right arm in 
a sitting position after a five minutes rest. Two independent consecutive measurements 
of systolic and diastolic blood pressure were taken and the mean of the measurements 
was used in the analyses.  
4.4 Assessment of serum lipids and lipoproteins 
All venous blood samples were taken after a 12 hour fast by 10.00 a.m. without stasis. 
Serum total cholesterol (CHOD-PAP, Roche Diagnostics GmbH, Mannheim, Germany 
(Studies I-III) and Cholesterol, Thermo Electron Corporation, Finland (Study IV)) and 
triglycerides (GPO-PAP, Thermo Clinical Labsystems Oy, Finland (Studies I-III) and 
Triglycerides, Thermo Electron Corporation, Finland (Study IV)) were measured by 
enzymatic photometric methods. LDL cholesterol was calculated according to the 
Friedewald formula (267) (Studies I-III) and measured by an enzymatic photometric 
method (Study IV). HDL cholesterol was measured by an enzymatic photometric 
method (CHOL CHOD-PAP, Roche Diagnostics GmbH) in supernatant after 
precipitation with dextran sulphate and MgCl2 (Studies I-III) and using a direct 
enzymatic photometric method (Thermo Electron Corporation, Finland) (Study IV).
KONE Pro clinical chemistry analyzer (KONE, Finland) (Studies I-III) and KONELAB 
20XTi clinical chemistry analyzer (KONE, Finland) (Study IV) was used. 
4.5 Anthropometric measurements
Anthropometric measurements were performed based on WHO MONICA protocol 
(268), with the subject in light indoor clothing without shoes. Waist circumference (to 
the nearest 0.5 cm) was measured on bare skin, at the mid-distance between the bottom 
of the rib cage and the top of the iliac crest. Hip circumference (to the nearest 0.5 cm) 
was measured at the level of the trochanter majors. Subjects stood with their feet 12 cm 
apart with their weight equally distributed on each leg. The mean of two measurements 
of the circumferences was used in the analyses. In the 84 participants, the intra-class 
correlation for two study nurses between the mean of two waist assays was 0.995 
(P<0.0001) and between mean of two hip assays 0.981 (P<0.0001) during the same 
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study visit in 2003 (Studies I-III). The coefficient of variation for these measures was 
0.7% for waist and 0.5% for hip. Body weight with a 0.1 kg precision was measured 
using a digital scale. Body height was measured with a 0.1 cm precision using a metal-
scaled height meter. BMI was calculated as weight divided by height squared (kg/m2).
4.6 Assessment of glucose tolerance and definition of diabetes 
After a 12 hour fast, the hexokinase method (Glucose, Thermo Clinical Labsystems Oy, 
Espoo, Finland) was used for blood glucose analyses (Studies I-III) or plasma glucose 
analyses (Study IV). In Study IV, oral post-challenge glucose tolerance test (OGTT) 
with a 75 g glucose load was carried out in the morning by 10.00 a.m. Subjects with no 
previously diagnosed type 2 diabetes underwent the OGTT. The blood samples were 
taken in the fasting state, and at 30, 60 and 120 minutes after the glucose load, the 
maximum deviation allowed was ±3 minutes. In addition to a 12 hour fast, the subjects 
were instructed to abstain from alcohol intake for three days, heavy physical activity for 
one day and smoking for 12 hours before the examination. They were asked to arrive 
the study center by bus/ car. 
Subjects were classified into 4 groups according to their glucose tolerance status using 
the WHO criteria (269). Those with normal glucose tolerance (NGT) had a fasting 
plasma glucose level <6.1 mmol/l and a 2-hour post-challenge glucose level <7.8 
mmol/l. Those with IFG had a fasting plasma glucose level between 6.1 mmol/l and 6.9 
mmol/l and a 2-hour post-challenge glucose level <7.8 mmol/l. Those with IGT had a 
fasting plasma glucose level <7.0 mmol/l and a 2-hour post-challenge glucose level 
between 7.8 and 11.1 mmol/l. Subjects were classified as having type 2 diabetes if they 
reported having diabetes diagnosed by a physician or had a fasting plasma glucose level 
7.0 mmol/l or a 2-hour post-challenge glucose level 11.1 mmol/l. The subjects with 
type 1 diabetes or type 2 diabetes, or who refused to participate in the OGTT (n=201)
were classified as having NGT if the fasting plasma glucose level was <6.1 mmol/l or 
IFG if the fasting plasma glucose level was 6.1 to 6.9 mmol/l or type 2 diabetes if they 
reported having type 2 diabetes diagnosed by a physician or their fasting plasma glucose 
level was 7.0 mmol/l. 
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4.7 Definition of metabolic syndrome 
The metabolic syndrome was defined by the National Cholesterol Education Program 
criteria (270), summing up the category scores (0=low risk, 1=increased risk) for blood 
pressure, blood/plasma glucose, HDL cholesterol, triglycerides and waist circumference
(Table 5). The existence of at least three risk factors was defined as the metabolic 
syndrome (270) (Table 5).  
Table 5. Individual components of the metabolic syndrome defined by NCEP  
Component Criteria
Blood pressure 130/85 mm Hg and/or use of antihypertensive medication 
Blood/Plasma glucose 6.1 mmol/l 
HDL cholesterol <1.29 mmol/l in women or <1.03 mmol/l in men 
Triglycerides 1.7 mmol/l 
Waist circumference >88 cm in women or >102 cm in men 
NCEP; the National Cholesterol Education Program criteria (270). 
4.8 Assessment of carotid atherosclerosis
Carotid artery atherosclerosis was assessed noninvasively by B-mode ultrasonography 
(185,271). Certified sonographers measured carotid artery IMT, while being scanned 
the subject was in the supine position, with the head turned 45º from the side. An 
ultrasound device with a high-resolution 10-MHz transducer was used, adhering to a 
standardized and pretested protocol. At each examination, the sonographer used three 
different standardized scanning angles including lateral (45º from vertical axis), anterior 
(20-30º) and posterior (50-60º) projection. The scannings were recorded on super VHS 
videotape. The same sonographer read all the scannings in both study years. The 
sonographer measured carotid IMT of the far wall of the right and left carotid arteries. 
The carotid IMT measurement extended to the longest wall region where the lumen-
intima and media-adventitia boundaries could be clearly identified by an automated 
edge-detection program on the basis of the active contour (272). We used the mean of 
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left and right carotid bifurcation IMT in the statistical analyses, because arterial 
bifurcations are prone to local plaque formation (138).  
4.9 Assessment of low-grade inflammation 
Serum hsCRP concentrations were measured by a commercial immunoassay 
(IMMULITE 2000 High-Sensitivity CRP, Diagnostic Products Corp., Los Angeles, CA, 
USA) using the IMMULITE 2000 Analyzer (Diagnostic Products Corp.). In the 97 
participants, the intra-class correlation between two hsCRP assays during the same 
study visit was >0.999 (P<0.0001) at baseline and >0.997 (P<0.0001) at 12-year follow-
up. The coefficient of variation was 1.7% at baseline and 3.6% at 12-year follow-up. 
Blood samples for hsCRP were taken at baseline and 12-year follow-up and were stored 
at -80°C until analysis in 2005.
4.10 Assessment of lifestyle factors 
Alcohol consumption (drinks/ previous week) (Studies I-IV), smoking (no vs. yes) 
(Studies I-III) and (never/ former/ current) (Study IV) and physical activity which lasts 
at least 30 minutes per session and causes breathlessness and sweating (sessions/ week) 
(Studies I-III) were assessed using a self-administered questionnaire.  
4.11 Assessment of diseases, medications and socioeconomic status 
Studies I-III 
The women completed a self-administered questionnaire on diseases diagnosed by a 
physician in the previous year (no vs. yes) and medications in a previous week (no vs. 
yes). A subject was considered to have prevalent cardiovascular disease (CVD) if she 
reported coronary heart disease (CHD), cardiac insufficiency and ischemic or
haemorrhagic cerebrovascular stroke (Studies I and III) or CHD and cardiac 
insufficiency (Study II). A subject was considered to have prevalent CHD if she 
reported to have angina pectoris or myocardial infarction. The use of hormone 
replacement therapy (no vs. yes) and education (years) were enquired at baseline. 
Depressive symptoms were assessed using the Zung self-report 20-item scale (273). The 
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item scores were summed up with a maximum score of 80 points, >50 points indicating 
depressive symptoms (273).  
Study IV
The subjects completed a self-administered questionnaire on diseases diagnosed by a 
physician (no vs. yes) and medications. A subject was considered to have prevalent 
CVD if he/she reported CHD, (ischemic or haemorrhagic) cerebrovascular stroke, 
transient ischemic attack, cardiac insufficiency, arrhythmia or lower extremity 
peripheral artery disease. A subject was considered to have prevalent CHD if he/she 
reported having angina pectoris, myocardial infarction, bypass coronary artery surgery 
or percutaneous transluminal coronary artery angioplasty. The use of hormone 
replacement therapy (no vs. yes) and education (years) were ascertained. Depressive 
symptoms were assessed using the 20-item scale, the Center of Epidemiological Studies 
Depression Scale (CES-D) (274). The item scores were summed up with a maximum 
score of 60 points, 16 points indicating depressive symptoms (274). 
4.12 Assessment of brain-derived neurotrophic factor 
Blood samples were drawn by 10.00 a.m. into glass tubes containing EDTA, which 
were spun immediately at 3000 x g for 10 min. Plasma was isolated and stored at -80 ºC
until analyzed. Plasma concentrations of BDNF were measured by enzyme-linked
immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, USA). After 
thawing, samples were centrifuged at 10000 x g for 10 min at 4 ºC for complete platelet 
removal. Samples were analyzed in duplicate and mean concentrations were calculated. 
A coefficient of variability in duplicates d10% was considered acceptable. The 
interassay coefficient of variability was lower than 13%. 
4.13 Statistical methods 
In Studies I-III, the scores of memory and cognitive speed were converted to 
standardized z-scores. In standardized z-scoring, the individual values of the variable 
are scaled so that the mean is zero and standard deviation is 1. Z-scoring has no effect 
on the distribution of the variable or its association with other variables. The z-values 
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for the Letter-digit Substitution Test were reversed. A sum of z-scores from the Word 
Recall Test and the prospective memory test was computed to describe memory. 
Similarly, the sum of z-scores from the Letter-digit Substitution Test and the Stroop 
Test was used to describe cognitive speed. The MMSE score of 25 was defined as 
good general cognition. This cut-off point was used in the analyses. The confounding 
variables were chosen for the analyses based on their known association with dependent 
and independent variables as well as to avoid co-linearity. In all studies, the level of 
significance was set at P<0.05. The analyses were conducted using the SPSS for 
Windows, Release 11.5 (SPSS Inc., Chicago, IL). 
4.13.1 Study I
For statistical analyses, z-scores were dichotomised at median (0.115 for memory and  
-0.266 for cognitive speed), and a "good" memory was defined as a score above the 
median and a "good" cognitive speed was defined as a score below the median. 
Differences in characteristics of women with or without metabolic syndrome were 
analysed using Independent-Samples t-test or Ԟ2-test as appropriate. Analysis of 
covariance was used to test for an association between the metabolic risk factors at 
baseline and memory, cognitive speed and the MMSE score at 12-year follow-up. The 
associations of metabolic syndrome and single metabolic risk factors at baseline and at 
12-year follow-up with the risk of having poor memory, poor cognitive speed, and low 
MMSE score were analysed using multiple logistic regression analysis. Data were first 
adjusted for age, education and depression, and further for hormone replacement 
therapy, BMI and prevalent cardiovascular disease, including coronary heart disease, 
cardiac insufficiency and stroke.  
4.13.2 Study II
Differences in the basic characteristics at baseline and at the 12-year follow-up were 
analyzed using Independent-Samples t-test or Ԟ2-test, and changes between study years 
by using Paired-Samples t-test or McNemar-test as appropriate. Correlation coefficients 
were calculated. The association between IMT and cognitive functions were analyzed 
separately with linear regression analysis. The association across IMT tertiles and 
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memory or cognitive speed was tested using analysis of covariance, and a linear trend 
between these variables was tested using multivariate linear regression analysis. Since 
the distribution of MMSE was skewed, even after logarithmic transformation, the 
association between IMT and MMSE was studied using logistic regression analysis. 
The women who had a stroke were excluded from the analyses. The analyses were 
adjusted for age, education, depression, type 2 diabetes, plasma LDL cholesterol, 
systolic blood pressure, prevalent cardiovascular disease (coronary heart disease, 
cardiac insufficiency), the use of hormone replacement therapy, physical activity, 
alcohol consumption and smoking.  
4.13.3 Study III 
Serum hsCRP concentration was categorized as low (<1.0 mg/L), average (1.0 to 3.0 
mg/L), and high (>3.0 mg/L) according to the statement for healthcare professionals 
from the Centers for Disease Control and Prevention and the American Heart 
Association (157). Differences in the characteristics of women with low, average or 
high hsCRP levels were assessed using analysis of variance or Ԟ2 -test as appropriate. 
The associations of hsCRP with memory and cognitive speed were analysed with linear 
regression analyses. The differences in the means of memory among the hsCRP tertiles 
were tested using analysis of covariance, and the linear trend across the tertiles was 
derived from linear regression analysis. Analyses were first adjusted for age, education, 
depression (model 1), and then additionally for the use of hormone replacement therapy, 
smoking and LDL cholesterol and BMI (model 2). However, we re-ran the analyses 
controlling also for fasting blood glucose (correlated significantly with LDL 
cholesterol) and systolic blood pressure (correlated significantly with hormone 
replacement therapy) at baseline. Since the distribution of hsCRP was skewed at 
baseline and 12-year follow-up, logarithmic transformation was used. Since the 
distribution of MMSE was skewed, even after logarithmic transformation, logistic 
regression analysis was used.
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4.13.4 Study IV
Since the distribution of BDNF was skewed, log-transformation was used. The 
distributions of individual tests of the CERAD test battery were skewed even after log-
transformation.  
Differences in the characteristics between men and women were analysed using 
Independent-Samples t-test or Ȥ2-test as appropriate. P-value for difference between 
men and women is derived from log transformed data as appropriate. Based on recent 
norms in a Finnish population, the individual tests of the CERAD were dichotomized at 
the lowest decile (266). The associations of BDNF with the individual tests of the 
CERAD were analysed separately in men and women using logistic regression analysis 
because of the skewed distributions of the tests even after log-transformation. Data are 
presented as odds ratios, Nagelkerke R-squares (ability of the model to explain the 
dependent variable), Wald's test quantity (explain whether odds ratios vary significantly 
from 1) and P-values. The data  were adjusted for age, education, depression, impaired 
glucose metabolism (IFG, IGT, type 2 diabetes), cardiovascular disease (coronary heart 
disease, stroke, transient ischemic attack, cardiac insufficiency, arrhythmias, lower 
extremity peripheral artery disease), antihypertensive medication, lipid lowering 
medication, the use of sex hormones in women, smoking, and alcohol consumption. In 
further analyses, the data were adjusted also for waist circumference. 
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5 RESULTS 
5.1 Characteristics of the study population 
5.1.1 Studies I–III 
Basic and clinical characteristics of the 113 women at baseline and at 12-year follow-up 
are presented in Table 6. For further analyses, the participants were categorized 
according to whether or not they had the metabolic syndrome (Study I), with or without 
data of carotid intima-media thickness (Study II) and levels of high sensitivity CRP 
(Study III) at baseline and at follow-up. The mean duration of formal education was 8.3
years. At baseline, none of the women had diabetes, and during the 12-years the 
prevalence of type 2 diabetes increased from 0 to 12 cases. Of the women, 27%, used 
hormone replacement therapy.
The non-participants (n=89) were older (65.6 vs. 63.9 years, P<0.001) and less 
educated (7.0 vs. 8.5 years, P=0.004) and had lower MMSE score (27.5 vs. 28.6 points, 
P=0.002), higher weight (72.4 vs. 67.9 kg, P=0.003) and BMI (29.2 vs. 27.4, P=0.004),
greater waist circumference (88.0 vs. 83.4 cm, P= 0.002) and greater hip circumference 
(102.0 vs. 98.8 cm, P=0.025), lower HDL cholesterol (1.5 vs. 1.6 mmol/l, P=0.015),
higher triglycerides (1.6 vs. 1.2 mmol/l, P=0.008), systolic blood pressure (161.3 vs. 
155.5 mm Hg, P=0.052) and diastolic blood pressure (91.9 vs. 88.5 mm Hg, P=0.023), 
as well as more type 2 diabetes (5 vs. 0%, P=0.023) and metabolic risk factors (2.1 vs. 
1.6, P<0.001) at baseline than the participants.
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Table 6. Basic and clinical characteristics of the 113 women at baseline and at 12-year follow-
up
At baseline At follow-up P-value
Age, years 63.9 (3.1)   75.3 (3.0) <0.001
Memory, z-value*  0.061 (2.71) 
Cognitive speed, z-value * -0.059 (2.33) 
MMSE**, points†  28.6 (1.8)   25.8 (2.4) <0.001
Weight, kg    67.9 (10.7)   68.4 (12.1)   0.354 
Height, cm 157.6 (5.3) 155.5 (5.5) <0.001
Waist circumference, cm    83.4 (10.6)   91.8 (11.6) <0.001
Hip circumference, cm    98.8 (10.3) 102.9 (8.7) <0.001
Body mass index** 27.4 (4.4)   28.1 (4.9)   0.002 
Blood glucose, mmol/l   4.8 (0.6)     5.3 (1.0) <0.001
Serum total cholesterol, mmol/l   6.2 (1.0)     5.3 (0.9) <0.001
Serum LDL** cholesterol, mmol/l   4.1 (0.9)     3.5 (0.8) <0.001
Serum HDL** cholesterol, mmol/l   1.6 (0.3)     1.3 (0.3) <0.001
Serum triglycerides, mmol/l     1.21 (0.4)     1.17 (0.5)   0.399 
Serum high sensitivity C-reactive protein, mg/l ‡    2.7 (7.24)     2.4 (3.35)   0.643
Systolic blood pressure, mm Hg 155.5 (21.9) 141.7 (19.5) <0.001
Diastolic blood pressure, mm Hg 88.5 (10.1)   71.9 (9.6) <0.001
History of stroke, % 4 8   0.063 
Prevalent cardiovascular disease**, % 19 29   0.008 
Prevalent depressive symptoms, % 1 3   0.625 
Use of antihypertensive medication, % 24 55 <0.001
Use of lipid lowering medication, % 6 34 <0.001
Physical activity, 2 times/week, % 63 88 <0.001
Smoking status, % 7 4   0.219 
Alcohol consumption, drinks/week   0.6 (1.3)     0.7 (1.6)   0.685 
Carotid artery intima-media thickness, mm §     1.03 (0.3)     1.25 (0.3) <0.001
Metabolic risk factors, NCEP**, sum   1.5 (0.9)     2.4 (1.1) <0.001
Metabolic syndrome, NCEP**, % 13 48 <0.001
      Values are means (± SD) or percentages (%) and Paired-Samples t-test, Wilcoxon-test,  
      Sci-square-test or McNemar-test was used as appropriate. 
* Data were available for 109 women, † 104 women, ‡ 107 women and P-value for difference is 
derived from log transformed data, and § 59 women. 
**MMSE, Mini-Mental State Examination; Body mass index, calculated as weight divided by 
height squared (kg/m2); LDL, Low-density lipoprotein; HDL, High-density lipoprotein; 
Cardiovascular disease includes coronary heart disease (angina pectoris, myocardial infarction), 
cardiac insufficiency; NCEP, the National Cholesterol Education Program criteria (270).
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5.1.2 Study IV 
Basic and clinical characteristics of the participants who attended all three baseline 
visits are presented in Table 7. The women had higher plasma BDNF levels (1735.9 (± 
SD 1466.2) vs. 1494.7 (± SD 1448.0) pg/ml, P<0.001) compared to men. Data for 
BDNF levels were available for 687 men and 707 women. 
The non-participants (those who dropped out during baseline examinations n=69) 
were older (69.7 vs. 66.5 years, P<0.001), less educated (8.9 vs. 11.2 years, P<0.001), 
had lower MMSE score (26.0 vs. 27.5 points, P<0.001), height (163.2 vs. 166.7 cm, 
P=0.020), and serum HDL cholesterol level (1.5 vs. 1.7 mmol/l, P=0.003), greater 
weight (81.9 vs. 77.1 kg, P=0.049), waist circumference (102.2 vs. 93.9 cm, P<0.001), 
hip circumference (107.4 vs. 100.9 cm, P<0.001) and BMI (30.7 vs. 27.7, P<0.001), 
higher plasma glucose level (6.3 vs. 5.8 mmol/l, P=0.003) and serum triglyceride level 
(1.6 vs. 1.3 mmol/l, P=0.028) and more metabolic risk factors (2.4 vs. 1.9, P=0.001), 
depressive symptoms (34.6 vs. 13.2%, P<0.001), coronary heart disease (32.3 vs. 
14.7%, P<0.001) and stroke (13.1 vs. 4.1%, P=0.001), worse smoking status (never 40.3 
vs. 54.6%, former 35.5 vs. 34.7%, current 24.2 vs. 10.7%, P=0.003) and glucose 
tolerance (normal glucose tolerance 52.2 vs. 65.8%, impaired fasting glucose 24.6 vs. 
10.4%, impaired glucose tolerance 1.4 vs. 10.8% and diabetes mellitus 21.7 vs. 13.0%, 
P<0.001) and they were less likely to use hormone replacement therapy (10.0 vs. 
26.4%, P=0.004) than the participants. In individual tests of the CERAD battery, the 
non-participants performed worse in Verbal Fluency Test (20.8 vs. 24.0 words/minute, 
P=0.001), Word Naming Test (12.4 vs. 13.2 words/ out of 15 words, P=0.006), MMSE 
Score (26.0 vs. 27.5 points, P<0.001), Word List Learning Score (19.6 vs. 21.8 words/ 
out of 30 words, P<0.001), Constructional Praxis Score (9.1 vs. 9.6 points, P=0.001), 
Word List Recall Score (6.3 vs. 7.2 words/ out of 10 words, P=0.001), Word List 
Saving Score (80.3 vs. 85.5%, P=0.020), and Clock Drawing Test (5.0 vs. 5.3 points, 
P=042) than the participants. 
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Table 7. Basic and clinical characteristics of the 1410 men and women  
Men
(n=696)
Women
(n=714)
P-value
Age, years   66.3 (5.4)   66.6 (5.3)   0.259 
Education, years   11.1 (3.9)   11.3 (3.8)   0.122 
MMSE*, points   27.6 (2.0)   27.5 (2.0)   0.349 
Height, cm      173.6 (6.1) 159.9 (5.9) <0.001
Weight, kg    83.6 (13.7)    70.7 (13.1) <0.001
Body mass index*   27.7 (4.0)   27.6 (5.0)   0.811 
Waist circumference, cm    99.0 (11.2)    88.9 (13.0) <0.001
Hip circumference, cm        99.8 (8.0)      102.0 (9.9) <0.001
Glucose tolerance status, % <0.001
     Normal glucose tolerance 
     Impaired fasting glucose   
     Impaired glucose tolerance   
     Diabetes mellitus* 
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14
11
16
73
7
10
10
Fasting plasma glucose, mmol/l   6.0 (1.1)   5.7 (0.8 <0.001
Serum total cholesterol, mmol/l   4.9 (0.9)    5.2 (0.9) <0.001
Serum LDL* cholesterol, mmol/l    3.2 (0.8)    3.2 (0.8)   0.238 
Serum HDL* cholesterol, mmol/l   1.5 (0.4)    1.9 (0.5) <0.001
Serum triglycerides, mmol/l   1.4 (0.8)    1.3 (0.6)   0.087 
Systolic blood pressure, mm Hg  145.3 (18.8)   150.2 (21.0) <0.001
Diastolic blood pressure, mm Hg  84.2 (9.3)   82.4 (9.2) <0.001
Metabolic risk factors, NCEP*, sum   1.9 (1.1)    1.9 (1.1)   0.387 
Alcohol consumption, drinks/ week   6.4 (8.2)    2.2 (4.2) <0.001
Smoking status, %     <0.001
     Never 
     Former  
     Current 
35
51
14
74
19
7
History of stroke, % 5 4   0.525 
Prevalent hypertension, % 45 47   0.463 
Prevalent cardiovascular disease*, % 54 46   0.007 
Prevalent depressive symptoms, % 11 15   0.020 
Use of sex hormones, % 4 49 <0.001
Use of antihypertensive medication, % 35 35   0.810 
Use of lipid lowering medication, % 41 43   0.610 
          Values are means (± SD) or percentages (%) and Independent-Samples t-test, Mann-Whitney U-
test or Sci-square-test was used as appropriate. *MMSE, Mini-Mental State Examination; Body 
mass index, calculated as weight divided by height squared (kg/m2); Diabetes mellitus, type 2 
diabetes including 4 individuals with type 1 diabetes; LDL, Low-density lipoprotein; HDL, 
High density lipoprotein; NCEP, the National Cholesterol Education Program criteria; 
Cardiovascular disease includes coronary heart disease, stroke, transient ischemic attack, 
cardiac insufficiency, arrhythmia, lower extremity peripheral artery disease.  
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5.2 Metabolic syndrome and cognitive function (Study I) 
At baseline, 58% of the women had one, 27% had two, 9% had three and 4% had four 
metabolic risk factors. There was no statistically significant difference in numbers of 
smokers (P=0.286) or users of hormone replacement therapy (P=0.073) between women 
with the metabolic syndrome and those without it. The women with or without the 
metabolic syndrome did not differ in terms of age, education, depression, the MMSE 
score, alcohol consumption, or prevalence of cardiovascular disease. 
At 12-year follow-up, 23% of the women had one, 27% had two, 36% had three, 11% 
had four, and 2% had five metabolic risk factors. Women with the metabolic syndrome 
were less likely to be physically active (P=0.019) and tended to have a poorer memory 
(P=0.083) than those without it. The prevalence of metabolic syndrome increased from 
13% at baseline to 49% at follow-up (P<0.001).
In longitudinal analyses, the presence of the metabolic syndrome at baseline 
associated with poor memory at 12-year follow-up (Figure 10A). The number of 
metabolic risk factors at baseline associated directly with memory at 12-year follow-up 
adjusted for baseline age, education and depression (Figure 11). Further adjustment for 
hormone replacement therapy did not alter the association (P=0.038 for trend). Women 
with the metabolic syndrome at baseline had a 4.27 (95% confidence interval 1.02 to 
17.90; P=0.047) times higher risk of having poor memory at the follow-up than women 
without it after these adjustments. Further adjustment for hormone replacement therapy 
did not have any effect on the relationship (odds ratio 4.12, 95% confidence interval 
0.97 to 17.53; P=0.056). Furthermore, adjustment for lipid lowering medication or the 
MMSE score did not change the results (result not shown). The presence of the 
metabolic syndrome at baseline was not significantly related with poor cognitive speed 
at follow-up (odds ratio 1.92, 95% confidence interval 0.54 to 6.82, P=0.319) or with 
the MMSE score (odds ratio 0.19, 95% confidence interval 0.02 to 1.58, P=0.123). 
In the cross-sectional analyses at 12-year follow-up, women with the metabolic 
syndrome had a 2.47 (95% confidence interval 1.05 to 5.85; P=0.039) times higher risk 
of having poor memory than those without it after adjustment for age, education and 
depression. Further adjustment for hormone replacement therapy did not alter the 
association (odds ratio 2.45, 95% confidence interval 1.03 to 5.80, P=0.042). Metabolic 
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syndrome was not significantly associated with poor cognitive speed (odds ratio 0.96, 
95% confidence interval 0.41 to 2.22, P=0.921) or the MMSE score (odds ratio 1.79, 
95% confidence interval 0.67 to 4.78, P=0.245).
With respect to the single metabolic risk factors, a low HDL cholesterol level at 
baseline was associated with poor memory at 12-year follow-up after adjustment for 
age, education and depression (Figure 10B). When all components of the metabolic 
syndrome were entered simultaneously as continuous variables into a logistic regression 
model with these covariates, only HDL cholesterol was independently associated with 
memory. The risk of having poor memory increased by 46.5% (95% confidence interval 
15% to 66%, P=0.008) with every 1 SD decrease in HDL cholesterol level. The 
magnitude of the association between HDL cholesterol and memory was unchanged 
after further adjustment for hormone replacement therapy, BMI and cardiovascular 
disease (result not shown). An increased waist circumference (odds ratio 2.00, 95% 
confidence interval 0.77 to 5.22, P=0.154) and higher triglyceride levels (odds ratio 
2.78, 95% confidence interval 0.73 to 10.62, P=0.136) at baseline tended to be 
associated with poor memory at follow-up. 
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 <1.0                          1.0-3.0                     
Figure 10. Memory (z-score) at 12-year follow-up in 101 elderly women with (n=88) or 
without (n=13) the metabolic syndrome and with lower (n=15) or higher (n=86) serum HDL 
cholesterol values at baseline adjusted for age, education and depression. 
Figure 11. Longitudinal association between number of metabolic risk factors (0-1 risk factors, 
n=61; 2 risk factors, n=27; 3 risk factors, n=13) at baseline and memory at 12-year follow-up 
adjusted for age, education and depression. 
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5.3 Atherosclerosis and cognitive function (Study II) 
The mean carotid IMT was 1.02 mm at baseline and 1.25 mm at follow-up (mean 
increase 0.23 mm, P<0.001). At baseline, carotid IMT correlated with prevalent 
hypertension (r=0.285, P=0.052). During the follow-up, the prevalences of hypertension 
(P<0.001) and cardiovascular disease increased (P<0.007) while the prevalence of 
hypercholesterolemia decreased (P<0.011). At 12-year follow-up, carotid IMT 
correlated with prevalent hypertension (r=0.313, P=0.032) and the use of drug treatment 
for hypertension (r=0.336, P=0.021). 
In cross-sectional analyses at 12-year follow-up, increased carotid IMT was associated 
with poor memory (Figure 12). On average, memory decreased by -0.275 standard 
deviations (SD) for every 0.1 mm increase in carotid IMT (Table 8). The association 
remained statistically significant after adjustment for all confounders (Table 8). The risk 
for poor memory increased with increasing carotid IMT tertiles after all adjustments 
(P=0.076 for linear trend). There was no association between carotid IMT and cognitive 
speed (Table 8) or MMSE score at 12-year follow-up (odds ratio 2.6, 95% confidence 
interval 0.4 to 15.3). 
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Figure 12. Cross-sectional association between carotid intima-media thickness (IMT) and 
memory at 12-year follow-up in 91 women.  
Table 8. Cross-sectional associations between increased carotid intima-media thickness (IMT) 
and risk of poor memory or cognitive speed at 12-year follow-up in 91 women 
Model 1 Model 2 
ȕ 95% CI P-value ȕ 95% CI P-value
Memory  -2.751   -4.58- -0.92 0.004 -2.054    -3.77-0.34  0.019 
Cognitive speed  1.177 -0.48-2.84  0.162  0.779 -0.84-2.41  0.342 
Data are from linear regression analyses. ȕ denotes standardized regression coefficient and 95% 
CI denotes 95% confidence interval. 
Model 1: Unadjusted 
Model 2: adjustments for age, education, depression, type 2 diabetes, low-density lipoprotein 
cholesterol, systolic blood pressure, cardiovascular disease (coronary heart disease, cardiac 
insufficiency), hormone replacement therapy, physical activity, alcohol consumption and 
smoking at the time of carotid IMT measures. 
Memory; sum of z-scores from the Word Recall Test and the prospective memory test. 
Cognitive speed; sum of z-scores from the Letter-digit Substitution Test and the Stroop Test. 
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In the longitudinal analyses, increased carotid IMT was associated with poor memory 
(Figure 13). Increased carotid IMT at baseline predicted poor memory and cognitive 
speed at 12-year follow-up (Table 9). On average, memory decreased by -0.500 SD and 
cognitive speed by 0.256 SD for every 0.1 mm increase in carotid IMT. The magnitude 
of the association between carotid IMT and memory or cognitive speed was unchanged 
after adjustment for all confounders (Table 9).  Further adjustment for baseline MMSE 
score did not change the associations (P=0.001 for memory and P=0.021 for cognitive 
speed). In this case also, the risk for poor memory (P=0.023 for linear trend) and 
cognitive speed (P=0.070 for linear trend) increased with increasing carotid IMT tertiles 
after all adjustments. With respect to memory, the difference between the lowest and the 
highest tertile was borderline significant (P=0.062) and the difference between the 
second and the highest tertile was significant (P=0.010) after all adjustments. There was 
no association between carotid IMT and the MMSE score (odds ratio 4.6, 95% 
confidence interval 0.1 to 150.4). There was no association between carotid IMT at 
baseline and the change of the MMSE score (standardized regression coefficient ȕ -
1.808, 95% confidence interval -4.82 to 1.20, P=0.230) after all adjustments including 
baseline MMSE.
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Figure 13.  Longitudinal association between carotid intima-media thickness (IMT) at baseline 
and memory at 12-year follow-up in 47 women. 
Table 9. Longitudinal associations between increased carotid intima-media thickness (IMT) at 
baseline and risk of poor memory or cognitive speed at 12-year follow-up in 47 women 
Mode 1 Model 2 
ȕ 95% CI P-value ȕ 95% CI P-value
Memory  -5.004  -7.74- -2.27 0.001 -4.851  -7.81- -1.89 0.002 
Cognitive speed  2.562 1.19-4.94 0.035  3.059 0.21-5.91 0.036 
Data are from linear regression analyses. ȕ denotes standardized regression coefficient and 95% 
CI denotes 95% confidence interval. 
Model 1: Unadjusted  
Model 2: adjustments for age, education, depression, low-density lipoprotein cholesterol, 
systolic blood pressure, cardiovascular disease (coronary heart disease, cardiac insufficiency), 
hormone replacement therapy, physical activity, alcohol consumption and smoking at the time 
of carotid IMT measures. 
Memory; sum of z-scores from the Word Recall Test and the prospective memory test. 
Cognitive speed; sum of z-scores from the Letter-digit Substitution Test and the Stroop Test. 
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5.4 Inflammation and cognitive function (Study III) 
At baseline, the median serum hsCRP was 1.12 mg/L, ranging from 0.01 to 70.14 mg/L 
(interquartile range 0.53 to 2.42). A total of 46 of the women had hsCRP <1.0 mg/L 
(low), 33 had 1.0-3.0 mg/L (average) and in 18 the level was >3.0 mg/L (high) at 
baseline. Women, with high serum hsCRP had more depressive symptoms (P<0.001 
between groups), higher fasting blood glucose (P=0.040 between groups), higher 
systolic blood pressure levels (P=0.027 between groups), BMI (P=0.020 between 
groups) and waist circumference (P=0.073 between groups), and they were less likely to 
use hormone replacement therapy (P=0.065 between groups) than those with low 
hsCRP. There was no difference in the MMSE score across the CRP groups at baseline 
(P=0.980 between groups).
At 12-year follow-up, the median serum hsCRP was 1.02 mg/L, ranging from 0.01 to 
22.11 mg/L (interquartile range 0.36 to 2.66). The median hsCRP (P=0.506) or number 
of women in the three hsCRP groups (P=0.708) did not differ at baseline and at 12-year 
follow-up. At 12-year follow-up, hsCRP was associated with BMI (26.3 ± 4.3 in low, 
29.5 ± 3.9 in average, and 29.5 ± 5.6 in high hsCRP group, P=0.010 between groups) 
and waist circumference (87.9 ± 9.7 cm in low, 95.9 ± 10.6 cm in average, and 95.2 ± 
12.3 cm in high hsCRP group, P=0.002 between groups).  
In longitudinal analyses, higher baseline hsCRP was associated with poorer memory 
at 12-year follow-up (Table 10). Additional adjustment for blood glucose and systolic 
blood pressure slightly weakened the association (standardized regression coefficient ȕ -
0.758, 95% confidence interval -1.585 to 0.070, P=0.072). Memory at 12-year follow-
up worsened linearly with increasing hsCRP at baseline (Figure 14). There was no 
association between hsCRP at baseline and cognitive speed (Table 10) or the MMSE 
score (odds ratio 0.56, 95% confidence interval 0.256 to 1.232, P=0.150) at 12-year 
follow-up.
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Table 10. Longitudinal association between baseline serum high sensitivity C-reactive protein 
(hsCRP) concentration and memory and cognitive speed at follow-up  
Model 1 Model 2
ȕ 95% CI P-value ȕ 95% CI P-value
Memory -0.842   -1.602- -0.083 0.030 -0.817  -1.630- -0.004 0.049 
Cognitive speed -0.199 -0.893- 0.469 0.571 -0.091 -0.831- 0.649 0.808
Data are from linear regression analyses. ȕ denotes standardized regression coefficient and 95% 
CI denotes 95% confidence interval. 
Model 1. adjusted for age, education and depression.
Model 2. adjusted for variables in model 1 and the use of hormone replacement therapy, 
smoking, serum low-density lipoprotein cholesterol and body mass index at the time of hsCRP 
measurements. 
Memory; sum of z-scores from the Word Recall Test and the prospective memory test. 
Cognitive speed; sum of z-scores from the Letter-digit Substitution Test and the Stroop Test. 
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Figure 14. Memory (sum of z-scores from the Word Recall Test and the prospective memory 
test) at 12-year follow-up in women with low (<1.0 mg/L, n=46 ), average (1.0-3.0 mg/L, 
n=33), or high (>3.0 mg/L, n=18) serum high sensitivity C-reactive protein (hsCRP) 
concentrations at baseline adjusted for age, education, depression, the use of hormone 
replacement therapy, smoking, serum low-density lipoprotein cholesterol and body mass index 
at the time of hsCRP measurements. 
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In cross-sectional analyses at 12-year follow-up, higher hsCRP was associated with 
poorer memory either without adjustment or after adjustment for age, education and 
depression (standardized regression coefficient ȕ -0.757, 95% confidence interval
-1.491 to -0.023, P=0.043) and further adjustment for the use of hormone replacement 
therapy, smoking, serum LDL cholesterol and BMI (ȕ=-0.709, 95% confidence interval 
-1.461 to 0.043, P=0.064). Additional adjustment for blood glucose and systolic blood 
pressure weakened slightly the association (ȕ=-0.688, CI 95% -1.446 to 0.070, 
P=0.075). HsCRP was not associated with cognitive speed (ȕ=-0.049, CI 95% -0.728 to 
0.630, P=0.886) or the MMSE score (odds ratio 0.91, 95% confidence interval 0.452 to 
1.851, P=0.803) at 12-year follow-up. 
5.5 Brain-derived neurotrophic factor and cognitive function (Study IV)
Characteristics of subjects
The characteristics of the subjects are presented in Table 11. The age range was from 57 
to 79 years. Women had a higher mean plasma BDNF level than men (1720.9 vs. 
1495.0 pg/ml, P<0.001). There were no differences in men or women in BDNF levels 
between those 65 years of age and those who were older or between individuals with 
depression and those without it. In men, mean plasma BDNF level was lower in those 
with BMI  25 compared to those with BMI <25 (1455.4 pg/ml vs. 1617.8 pg/ml, 
P=0.027).
   Women performed better in Word List Memory Score (P<0.001), Word List Recall 
Score (P<0.001), Word List Saving Score (P=0.020), Word List Recognition Score 
(P<0.001) and Clock Drawing Score (P=0.006), but worse in Naming Test (P<0.001) 
compared to men (Table 12). The norms used in the DR's EXTRA Study and in Finnish 
population are presented in Table 13.
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Table 11. Basic and clinical characteristics of the subjects  
Women
(n=705)
Men
(n=684)
P-value
Age, years  66.6 (5.3) 66.3 (5.4)   0.303 
Education, years 11.3 (3.8) 11.1 (3.9)   0.137 
MMSE*, points 27.5 (2.0) 27.6 (1.9)   0.396 
Body mass index* 27.6 (5.0) 27.6 (4.0)   0.999 
Waist circumference, cm  88.9 (13.0)  98.8 (11.1) <0.001
Fasting plasma glucose, mmol/l  5.7 (0.8)  6.0 (1.0) <0.001
Serum LDL* cholesterol, mmol/l     3.2 (0.8)  3.2 (0.8)   0.245 
Serum HDL* cholesterol, mmol/l  1.9 (0.5)  1.5 (0.4) <0.001
Serum triglycerides, mmol/l  1.3 (0.6)  1.4 (0.8)   0.105 
Systolic blood pressure, mm Hg 150.1 (21.1)    145.3 (18.9) <0.001
Diastolic blood pressure, mm Hg       82.4 (9.2)      84.2 (9.3) <0.001
Glucose tolerance status, % <0.001
     Normal glucose tolerance 73 59
     Impaired fasting glucose 7 14
     Impaired glucose tolerance 10 11
     Type 2 diabetes 10 16
Prevalent hypertension, % 47 45   0.441 
Prevalent cardiovascular diseases*, % 33 40   0.006 
Prevalent depressive symptoms, % 16 11   0.013 
History of stroke, % 4 5   0.350 
Use of sex hormones, % 49 4 <0.001
Use of antihypertensive medication, % 43 41   0.580 
Use of lipid lowering medication, % 35 35   0.807 
Alcohol consumption, drinks/week  2.2 (4.3)  6.4 (8.1) <0.001
Smoking status, %   <0.001
     Never 74 35
     Current  19 50
     Former 7 15
Values are means (± SD) from Independent-Samples t-test or Mann-Whitney U-test or 
percentages from Ȥ2-test.
* MMSE, Mini-Mental State Examination; Body mass index, calculated by dividing weight by 
height squared (kg/m2); LDL, low-density lipoprotein; HDL, high-density lipoprotein. 
Cardiovascular diseases include coronary heart disease, stroke, transient ischemic attack, 
cardiac insufficiency, arrhythmia, and lower extremity peripheral artery disease. 
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Table 12. Characteristics of the subjects in individual tests of the CERAD test battery 
Women
(n=705)
Men
(n=684)
P-value
Verbal Fluency, words/ minute 24.0 (6.0) 24.1 (6.6)  0.721 
Naming, words/ out of 15 words 12.8 (2.0) 13.6 (1.6) <0.001
MMSE, points 27.5 (2.0) 27.6 (1.9)  0.396 
Word List Memory, words/ out of 30 words 22.6 (3.5) 21.0 (3.7) <0.001
Constructional Praxis, points  9.3 (1.1)  9.6 (1.1)  0.827 
Word List Recall, words/ out of 10 words  7.5 (1.8)  6.8 (1.9) <0.001
Word List Saving Score, %  86.4 (15.3)  84.5 (16.7)  0.020 
Word List Recognition Score, % 97.0 (6.0) 95.6 (6.0) <0.001
Constructional Praxis Saving Score, %  90.7 (14.0)  92.0 (11.9)  0.121 
Clock Drawing, points  5.4 (1.0)  5.3 (1.0)  0.006 
      Values are means (± SD) and Mann-Whitney U-test was used unless otherwise indicated.  
Table 13. Norms for use of the CERAD test battery based on Finnish population and  
in the DR's EXTRA Study  
Finnish population DR's EXTRA Study* 
Verbal Fluency, words/ minute  <14  <17 
Naming, words/ out of 15 words  <10  <11 
MMSE, points  <25  <25 
Word List Memory, words/ out of 30 words  <15  <17 
Constructional Praxis, points <7 <9
Word List Recall, words/ out of 10 words - <5
Word List Saving Score, %  <61  <63 
Word List Recognition Score, %  <86  <90 
Constructional Praxis Saving Score, %  <25  <75 
Clock Drawing, points <4 <4
     *Based on recent data from a Finnish population (266), the individual 
      tests of the CERAD test battery were dichotomized at the lowest decile in the DR's EXTRA 
      Study.  
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Plasma BDNF and cognitive function 
Women in the lowest 10% of the CERAD scores had lower BDNF levels compared to 
women in the upper 90%. A significant difference was observed on Naming Test 
(P=0.005), MMSE Score (P=0.016), Word List Recall Score (P=0.018), Word List 
Saving Score (P=0.006) and Word List Recognition Score (P=0.018). In men, there 
were no such differences in any cognition test (P-values ranged from 0.086 to 0.803). 
   Decreased plasma BDNF levels were associated with impaired cognitive function in 
women (Table 14). In women, the risk for a low score in Naming Test increased by 
53%, MMSE by 60%, Word List Memory by 51%, Word List Recall by 52%, Word 
List Saving by 51% and Word List Recognition by 60% with one standard deviation 
(SD) decrease in plasma BDNF. A similar batter was observed also for other cognitive 
tests (Verbal Fluency, Constructional Praxis, Clock Drawing), but the associations 
between BDNF were not significant. Data were adjusted for age, education, depression, 
impaired glucose metabolism, cardiovascular disease, antihypertensive medication, lipid 
lowering medication, use of sex hormones, smoking and alcohol consumption. 
Additional adjustment for waist circumference did not change the magnitude of the 
associations. The magnitude of the association between BDNF and cognitive function 
was unchanged across unadjusted, age adjusted or fully adjusted analyses. 
   In the multivariate analyses, the use of sex hormones did not change the magnitude of 
the association between BDNF and cognitive function in women. Individuals who 
reported use of sex hormones performed better (P<0.05) in the tests of general cognitive 
function (MMSE), memory (Word List Recall), language (Naming) and executive 
function (Constructional Praxis). No statistically significant difference was found in 
other CERAD tests. 
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6 DISCUSSION 
6.1 Summary of main findings 
The main findings are summarised as follows: 
* Metabolic syndrome was associated with the risk of having poor memory in elderly 
women. With respect to the single risk factors, low level of HDL cholesterol was 
independently associated with the risk of having poor memory.  
* Peripheral atherosclerosis, measured ultrasonographically as carotid intima-media 
thickness, was associated with the risk of having poor memory and poor cognitive speed 
in elderly women.  
* High serum concentrations of high sensitivity C-reactive protein were associated with 
the risk of having poor memory in elderly women.  
* Decreased plasma brain-derived neurotrophic factor level was associated with 
impaired memory and general cognitive function in ageing women. The kind of 
association was not found in men.  
* No associations were found between cardiovascular risk factors and the Mini-Mental 
State Examination score in elderly women. 
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6.2 Methodological aspects 
6.2.1 Study population and design 
In Studies I-III, the population-based cohort of elderly women provided an opportunity 
to investigate the association between well-known cardiovascular risk factors and 
cognitive function over a long follow-up period. The present study made it possible to 
confirm the limited data between vascular risk factors and cognitive impairment. AD 
and dementia are more common in women than in men (40,41), and therefore it was 
justified to focus this research on elderly women. Even though the sample size was 
limited, our data were obtained from in-person measurements at the study centre. In 
many large studies, telephone interviews have been used in data collection, which may 
reduce their reliability. To evaluate cognitive function, we used a screening test for 
global cognitive function and a detailed test battery for memory and cognitive speed at 
follow-up. Thus, the prospective design remained partial. Since approximately 15% of 
the women had died, 15% had severe health problems, and 10% had other reasons for 
non-participation. The participants were quite aged, and though they were from the 
province of Kuopio, some of them would have had to travel a distance as much as 100 
kilometers from the research laboratory, which may partly explain the participation rate 
and selection of the study population. In many studies, the weakness is that cognitively 
impaired individuals are excluded at baseline, and many studies do not include data on 
individuals lost to follow-up (11). Individuals with cognitive decline are less likely to 
participate in clinical studies (275). In the present study, the participants were younger, 
better educated, healthier, and had better global cognitive function and a metabolic risk 
factor profile at baseline than the non-participants. Therefore the present results may be 
underestimated the prevalence in the entire population. In Studies I-III, it is not possible 
to make any inference of causality.  
In Study IV, there was an opportunity to investigate the association between 
neurotrophic factor level and cognitive function at baseline of a large ongoing 
randomized controlled trial. The study population was a representative population 
sample of ageing men and women living in the city of Kuopio. The only exclusion 
criteria for the intervention study were conditions that would have prevented safe 
engagement in exercise training, malignant diseases and other conditions preventing co-
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operation, as judged by the research physicians. Otherwise, those participants who had 
some diseases which might have affected cognitive function were not excluded. On the 
period, the individuals confirmed their willingness to participate in the study and 
baseline measurements, the most common reasons for not participating in the study 
were loss of motivation and unknown reasons, whereas during baseline measurements, 
the participants dropped-out for medical reasons (Figure 9). In epidemiological studies, 
the participation rate has decreased during the past 30 years, especially in recent years, 
and is approximately 50% to 70% at this moment (276). The participation rate in the 
present study was nearly 70%, evidence of rather high compliance when taking into 
consideration the age of the participants and the substantial demands of the study. We 
believe that the study population is representative and also that those who participated 
in baseline measurements were motivated. We collected data on those who dropped-out 
during baseline visits. Subsequently, this randomized controlled intervention study 
focused on exercise and nutrition which makes it possible to confirm our cross-sectional 
observations and to investigate dose-response relationship between lifestyle factors and 
cognitive function in specific age and gender groups. At the time, the study design does 
not make it possible to infer causality or more generalization of the results.   
6.2.2 Assessment of cognition 
The schedule of the cognitive measures was designed by experienced 
neuropsychologists. Before the study visits, the participants were informed about the 
measurements in a letter and trained study nurses performed the measures with standard 
protocols. Global cognitive function was measured using the MMSE score in all studies. 
The MMSE score is a well-known screening instrument that measures orientation, 
language, memory, concentration and constructional praxis (10), but it is within the 
normal range in most people with MCI (7). In addition to global cognitive function, a 
detailed evaluation of cognitive function was performed at the follow-up in Studies I-III 
and in Study IV. Poor performance on neuropsychological tests such as delayed recall, 
naming and executive functions are evidence of a risk for progression to dementia (7-9).
In the present studies, appropriate combinations of neuropsychological tests were used 
to identify those with incipient cognitive impairment. Furthermore, in all studies, 
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depressive symptoms were evaluated and data were carefully controlled for potential 
confounders, which is important especially in an elderly population where many factors 
may affect cognitive performance. We had no resources to use neuroimaging, and we 
had some missing data concerning cognition and other variables of interest.
In Studies I-III, memory and cognitive speed were only evaluated at follow-up, 
therefore it was not possible to examine the change in these functions that occurred 
during the follow-up. Thus, we could not exclude the possibility that some of the 
women had had mildly impaired cognition at baseline. However, at that time their 
global cognitive function had been good, only two of the women scored <25 at baseline, 
and even additional adjustment for baseline MMSE did not change the magnitude of the 
associations. There were no associations between the predisposing factors and global 
cognitive function, whereas the associations were perceived using more specific 
neuropsychological tests. We used a sum score of the two tests to characterize memory 
and cognitive speed, which may be more reliable than the use of only a single test. 
Since there were no specific cut-off points in the scores of memory and cognitive speed, 
we used the variables as continuous when appropriate. There is very little longitudinal 
population-based data available about the association between cardiovascular risk 
factors and detailed evaluated cognitive function examined in Studies I-III. Thus, we 
believe that the present results highlight the role of these modifiable risk factors in the 
development of MCI. 
In Study IV, we used the CERAD test battery which is considered to measure rather 
extensively cognitive domains that are prone to deficits in MCI and dementia (15). In all 
of the tests, we calculated specific cut-off points based on recent norms in a Finnish 
population (266). Age, gender and education are closely related to cognitive function, 
and they were taken into consideration when the cut-off points were calculated. The 
present study possibly revealed important information of development of cognitive 
impairment in ageing women. Even though CERAD is a broad and sensitive cognitive 
test battery, all cognitive processes that may or may not be affected by BDNF cannot be 
found out using this test battery. Cognitive function is a topical issue at the moment, and 
some of the participants were somewhat nervous at the beginning of the test session. 
The personal informative discussion before the start of the test session seemed to lessen 
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this stress. Early diagnosis of cognitive impairment is shown to decrease symptoms of 
anxiety and to elicit relief after receiving diagnostic accuracy (277). 
6.2.3 Assessment of risk factors
The schedule for the study visits and the measurements used were carefully designed. 
The instruments for study measures were calibrated, and the study personnel was 
trained before the study started (Studies I-IV). Body weight and height, waist and hip 
circumference as well as blood pressure are straight forward measures, and widely used 
in clinical studies. In anthropometric measurements, the differences between the study 
nurses may be greater than expected. However, we duplicated waist and hip 
circumference measures with two study nurses in 84 participants during the follow-up 
visit (Studies I-III). The intra-class correlation for the two nurses was 0.995 between 
waist measurements and 0.981 between hip measurements during the same study visit. 
The coefficient of variation was 0.7% for waist circumference and 0.5% for hip 
circumference. The anthropometric measurements were based on the MONICA protocol 
(268), and we used the mean of two measurements in statistical analyses. Ageing is 
associated with a redistribution of both fat and lean tissue within the body, and intra-
abdominal fat can be estimated by anthropometric measurements (278) easily and 
inexpensively. The measures of blood pressure were based on the general guidelines for 
the Finnish health care. In the statistical analyses, we used the mean of two consecutive 
measurements. The measurement of blood pressure is responsive to external factors, 
therefore the importance of standardized circumstances and meters used must be 
emphasized. In the present studies, differences between the study nurses and 
repeatability of the meters used were not tested, which may slightly limit the validity of 
the studies. Increased blood pressure and obesity in middle-age have been linked 
previously to cognitive impairment.  
The participants were informed about the laboratory measurements by letter. All 
laboratory assessments followed standard protocols and all blood samples were taken by 
experienced laboratory technicians and were stored as appropriate. Intra-class 
correlation between two hsCRP assays during the same study visit was >0.999 at 
baseline and >0.997 at 12-year follow-up. The coefficient of variation was 1.7% at 
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baseline and 3.6% at 12-year follow-up (Study III). We feel that the laboratory 
assessments and determinations were conducted in a reliable manner. High sensitivity 
CRP is a sensitive marker of systemic low-grade inflammation (157), and increased 
concentrations of hsCRP have been associated with impaired cognition (164,165,167). 
Furthermore, inflammation has been linked to the pathogenesis of cardiovascular 
disease (157,279), obesity and insulin resistance (280), which in turn have been 
associated with the risk of cognitive impairment (93,112). Serum BDNF levels 
measured by ELISA is suggested to represent a mixture of the proBDNF and mature 
BDNF forms (251). Therefore, we could not assess the association of each form of 
BDNF with cognition. However, mature BDNF is suggested to decrease more sharply 
than proBDNF in the early phase of Alzheimer's disease (249). Research into the 
association between biomarkers and cognitive function provides important 
supplemental information about the prediction and diagnosis of MCI and dementia. In 
Study IV, glucose tolerance was tested using the OGTT (269), which is a reliable 
method for identifying individuals in a pre-diabetic condition. The participants were 
categorized into four groups (normal fasting glucose, impaired fasting glucose, impaired 
glucose tolerance and type 2 diabetes) according to their glucose tolerance status using 
the WHO criteria (269). In many studies, the definition of diabetes has been based on 
self-reported medical history or fasting blood glucose concentrations. This means that 
individuals in a pre-diabetic condition or having undiagnosed diabetes have been 
overlooked. Glucose intolerance has been shown to disturb cognitive function and 
evoke functional and structural damage of the brain as well as an increase in the risk of 
vascular injuries (100,115). 
Diseases, medications, lifestyle factors and socio-economic status were assessed by a 
self-administered questionnaire, which is a practical and inexpensive method to 
implement. Data collection by questionnaires requires good design and well-defined 
instructions on how the questions are to be answered. To avoid misunderstandings and 
missing data it is useful to check the questionnaires as soon as they are received. In the 
present studies, the questionnaires were checked and completed when received, 
however there were some still missing data, which may partly have reduced the power 
in the statistical analyses. On the other hand, in population-based studies it is impossible 
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to obtain truly comprehensive data and as such, overestimation or underestimation is 
typical when lifestyle factors such as physical activity and nutrition are assessed by a 
self-administered questionnaire. For Study II, the data that evaluated strokes between 
baseline measurements and follow-up were obtained from the national hospital 
discharge register that covers the whole population in Finland and this is a reliable 
source of cardiovascular outcomes. Ischemic stroke increases the risk for dementia (50), 
although it may be reversible in a substantial proportion of patients within one year 
post-stroke (281). On the other hand, in self-report the subjects may be confused, for 
example differentiating between stroke and transient ischemic attack.  
The metabolic syndrome was defined by the National Cholesterol Education Program 
criteria (270). These criteria are simple to use in clinical evaluation and do not 
emphasize any of the features in the risk factor score as opposed to the other well 
known criteria (85). Clustering of metabolic risk factors is shown to be a greater risk for 
cognitive decline than its individual components. Individuals with metabolic syndrome 
are at an increased risk for vascular diseases such as type 2 diabetes and stroke and 
thereby for cognitive impairment. However, the specific cut-off values which are used 
in the most common criteria may not be suitable in the oldest old individuals. In late 
life, the presence of the metabolic syndrome may decelerate cognitive impairment 
(130), but more evidence is needed to support this assumption. 
Peripheral atherosclerosis was measured noninvasively as carotid artery intima-media 
thickness as previously reported (185,271). Certified sonographers performed the 
scannings according to a certain protocol and one study nurse read all the scannings. In 
Study II, no quality control measurements were performed, because this would have 
required an additional study visit. However, the women were so aged and one more visit 
might represented an additional unwelcome stress. The quality control measurements 
were performed in another study and they expressed high reliability (185). Carotid IMT 
has been considered to be a useful surrogate marker of atherosclerosis (282,283), and to 
be associated with an increased risk of coronary and cerebral events (284,285). Carotid 
IMT has a better sensitivity in detecting pre-clinical atherosclerosis compared to 
angiography (282). For the statistical analyses, we used the mean carotid IMT of left 
and right bifurcation, a location known to be prone to atherosclerosis, since it may be 
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subjected to alterations in blood flow such as decreased shear stress and increased 
turbulence in this area (138).
6.3 Results 
6.3.1 Metabolic syndrome and cognitive function (Study I) 
Metabolic disorders such as type 2 diabetes and metabolic syndrome are increasing in a 
dramatic manner throughout the world. The results of the present study are in 
accordance with a recent study examining the prevalence of metabolic syndrome among 
Finnish men and women over a decade (286). The present results when viewed in 
combination with previous findings (78,126,129) emphasize the role of metabolic 
syndrome in cognitive impairment. In the oldest old, opposing results have been found 
(130), likewise concerning the associations between cognition and high levels of blood 
pressure (65), cholesterol (71), glucose (130) and body weight (97,98). In the present 
study, the follow-up time was rather long and we used specific tests to evaluate the 
association between metabolic syndrome and cognitive function. Impairment in 
memory and executive functions typically precedes dementia, therefore the detailed 
evaluation of cognitive function was a useful way of identifying those at increased risk 
to convert dementia. Metabolic syndrome did not associate with the MMSE. 
   Insulin resistance, the pathophysiological feature of metabolic syndrome, and 
diabetes are deleterious to ageing-related cognitive function, especially memory. In the 
present study, the prevalence of type 2 diabetes increased 12% during the follow-up 
period, which may partly explain the association between metabolic syndrome and 
impaired memory. Type 2 diabetes, as well as associated diseases such as obesity and 
hypertension, have been suggested as pathogenetic mechanisms in AD and vascular 
dementia due to their interaction with inflammation and processing and deposition of 
beta-amyloid protein, a hallmark of AD (112,114). However, in late life, moderate 
overweight has been indicative of good cognitive status (287). In the present study, 
traditional risk factors such as blood pressure, blood glucose levels or waist 
circumference were not significantly associated with memory functions suggesting that 
metabolic syndrome may give some additive value in predicting the development of 
memory decline compared to the separate conventional risk factors. More research will 
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be needed to clarify the relative importance and putative interactions between single 
metabolic risk factors for cognitive impairment. On the other hand, some criticism has 
been raised against the definition of the metabolic syndrome, because some risk factors 
associated with insulin resistance, such as physical inactivity, are not included in the 
definition of the syndrome (288). 
Low serum levels of HDL cholesterol associated independently with poor memory 12 
years later. Our results are in agreement with recent cross-sectional findings reporting 
that lower HDL cholesterol levels are associated with impaired memory (289). It has 
been suggested that high HDL cholesterol levels may protect against hippocampal 
atrophy in elderly people (82). HDL is the main carrier of cholesterol into the brain and 
the availability of cholesterol improves synaptic growth and regeneration (81). As the 
predominant lipoprotein in the human brain, HDL cholesterol can also prevent 
inflammation (83) as well as inhibiting the aggregation and polymerisation of beta-
amyloid protein (84). Furthermore, low levels of HDL cholesterol are a known risk 
factor for cardiovascular disease (290), which in turn may lead to dementia. Further 
investigations in representative population samples should be conducted to study the 
additive values of metabolic syndrome beyond single risk factors and the relative 
importance of each risk factor for memory and cognition.  
6.3.2 Atherosclerosis and cognitive function (Study II) 
The present study is one of the first to report an association between increased IMT and 
poor memory and poor cognitive speed among relatively healthy elderly women over a 
long follow-up period. Previous findings have been mainly cross-sectional (144,147-
150), only a few have been population-based (144,150). The inconsistences between the 
findings may be partly related to differences in the study populations, follow-up times, 
and cognitive measures used. The development of atherosclerosis in carotid arteries is 
suggested to start with an increased IMT in the bifurcation, possibly due to alterations in 
the blood flow in this area (138,283). Thus, the bifurcation is the preferred site to 
measure pre-clinical atherosclerosis. Carotid IMT and carotid stenosis may represent a 
different phase of the atherosclerotic process (151), and thus, the effects on cognition 
may differ in a given population.
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Memory, executive functioning and perceptual speed may be impaired for several 
years before the clinical diagnosis of AD (291). The same cognitive domains appear to 
be implicated in normal ageing, but there is a lack of data of normative rates for age-
related cognitive decline. There is a considerable overlap in the risk factors, 
symptomatology, and pathophysiology of vascular dementia and AD (292), and thus, it 
may not be possible to make a sharp distinction between degenerative and vascular 
diseases, especially in elderly individuals. In view of these issues, we focused both on 
memory performance and cognitive speed/executive functions on specific 
neuropsychological tests without using any proposed diagnostic concepts, whose 
relevance in the general population is still unclear. In the present study, increased IMT 
was associated not only with poor cognitive speed but also with memory, but not with 
general cognitive functioning. This supports the view that sensitive measures of 
cognition are important when evaluating the effects of atherosclerosis on cognition (13). 
Vascular risk factors and diseases have been linked with an increased risk for 
cognitive decline, but the exact mechanisms underlying the association are still obscure.
Carotid IMT has been suggested as being a marker of medial hypertrophy but it is not 
synonymous with atherosclerosis (151). Carotid IMT has also been suggested as a 
predictive measure of target organ damage including microangiopathy in patients with 
essential hypertension (293). Thus, our findings indicate that the atherosclerotic process 
and end organ diseases of the arteries may be important in mediating the association 
between vascular risk factors and cognition. Atherosclerosis may impair cerebral blood 
flow and metabolism, and ultimately lead to neuronal dysfunction and cell death (294). 
Atherosclerosis also increases the risk of strokes and white matter lesions that may 
contribute to cognitive impairment. In addition, other vascular outcomes such as 
aberrations in the capillary ultrastructure in the brain and endothelial dysfunction may 
partly explain the observed associations. It will be crucial to study these issues in the 
future, especially in view of the fact that clarification of the vascular component in 
cognitive impairment may be useful in terms of prevention. Furthermore, in addition to 
traditional vascular risk factors, socio-economic inequality may be an important factor 
in the link between IMT and cognitive function (295). 
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The predictive role of cognitive impairment for subsequent dementia and loss of 
independence has been reported in a number of studies (296,297), and those individuals 
exhibiting cognitive impairment may represent an ideal group for targeted interventions. 
The observed relation between IMT and cognitive impairment may have implications 
for the prevention of cognitive impairment and dementia as vascular risk factors can be 
treated. Non-invasive assessment of arteries and the use of sensitive neuropsychological 
tests may become important tools in detecting those individuals with a high risk of 
suffering cognitive impairment, which, importantly, might be preventable by treatment 
aimed at achieving a reduction in the progression of atherosclerosis. 
6.3.3 Inflammation and cognitive function (Study III) 
Inflammation is suggested to be one of the key events in the pathogenesis of 
atherosclerosis and AD. The inflammatory response may contribute to neuronal 
dysfunction and lead to neuronal death in the brain. The present results are in 
accordance with previous studies indicating that increased low-grade inflammation is 
associated with cognitive impairment. Increased serum hsCRP concentrations have been 
associated with poor memory (164), poor global cognitive performance (165,166,168), 
vascular dementia (167) and AD (169,170) in previous population-based studies. In 
some studies no such association has been found (171,172). In the previous studies, the 
age-range of the participants has varied between 30 and 85 years, the follow-up time 
was generally rather short and very few studies have used a detailed evaluation of 
cognitive function, which may partly explain the dissimilarities between the studies, and 
represent limitations to attempts to generalization. In the present 12-year follow-up, we 
applied also a detailed evaluation of memory and cognitive speed, the domains which 
are known to be impaired before any clinical diagnosis of dementia (8). However, due 
to the lack of baseline data of these functions, we were not able to analyse the change in 
specific cognitive domains. HsCRP was not associated with global cognitive function.  
The present data may broaden the aspects on the association between inflammatory 
biomarkers and MCI. Since there are no generally accepted instruments to define the 
transition between normal cognitive function and MCI, in addition to commonly used 
neuropsychological tests, other tools such as biomarkers are recommended if one 
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wishes to obtain an accurate diagnosis (7,17,18). Limited data are available of the 
association between the role of inflammatory biomarkers and MCI (18). Cognitive 
impairment seems to have a common vascular etiology (60,64,104), and atherosclerosis 
may represent a chronic inflammatory process (184). On the other hand, inflammation 
increases cardiovascular risk (157,279), which in turn is associated with cognition. In 
the present study, adjustment for several vascular factors only slightly modified the 
association between hsCRP and cognition, which indicates that the association between 
high hsCPR and poor memory is not totally mediated through vascular factors. Thus, 
inflammatory markers such as hsCRP may represent an additional fact for inclusion in 
the global assessment of cardiovascular risk and cognitive impairment. 
6.3.4 Brain-derived neurotrophic factor and cognitive function (Study IV)  
Our study indicated that decreased plasma BDNF level was associated with impaired 
cognitive function in non-demented ageing women, but not in men. Furthermore, we 
observed that women have higher BDNF levels than men. To our knowledge, the 
present study is the first one examining the association between circulating BDNF level 
and cognitive function in an elderly general population.
   We observed that decreased BDNF levels were associated with impaired global 
cognitive function as well as impairment in specific components of memory. However 
the associations were not seen in tests measuring executive function. Low serum BDNF 
levels have been previously associated with MMSE scores in demented persons 
(247,248), but no previous data are available on its associations between specific 
cognitive domain in non-demented population. Decreased levels of BDNF mRNA in 
post-mortem hippocampus (259), temporal cortex (251,259) and parietal cortex (250), 
were seen in Alzheimer's disease. Downregulation of BDNF, including proBDNF 
(249,251), is suggested to be an event underlying early Alzheimer's disease (249). Both 
the number of BDNF immunopositive neurons and the intensity of immunostaining 
within cell bodies in hippocampus and temporal cortex appear to be decreased in 
Alzheimer's disease (251,259).
   BDNF plays a key role in modulating synaptic transmission and plasticity of neurons 
(236-240). Synaptic plasticity is thought to be the activity-dependent cellular 
 89 
mechanism for learning and memory, called long-term potentiation (LTP) (298,299). 
BDNF has been hypothesized to be an important factor in LTP (298-300), especially for 
the development of the late phase of LTP (241), a form of synaptic plasticity believed to 
underlie long-term memory (301). BDNF is important for consolidation of LTP 
especially in hippocampal region CA1 (298,299) an area which is vulnerable to 
neuronal pathology (302). BDNF has been demonstrated to modulate LTP indirectly by 
inhibiting synaptic fatigue (298). In BDNF knockout mice, synaptic fatigue (303) and 
impairment in LTP were enhanced (241,303). On the other hand, induction of LTP may 
increase BDNF mRNA levels in hippocampus (241). The findings from experimental 
studies indicating that BDNF modulates hippocampal LTP imply that BDNF may play a 
role in the regulation of learning and memory (299) and provide a biological basis for 
our finding.
   The gender difference for the association between plasma BDNF levels and cognitive 
function may be explained by sex hormones. The youngest women were 58 years of age 
and thus, almost all women were posmenopausal. Approximately half of the women 
used sex hormones. In multivariate analyses women who used sex hormones had better 
cognitive function. However, the use of sex hormones did not modify the association 
between BDNF and cognition. Altogether 28 men had prostate cancer and 11 of them 
had used sex hormones. Thus, these small numbers suggest that prostate cancer or usage 
of sex hormones in males were not major confounders for the association between 
BDNF and cognition.   
   Estrogen receptors are found in hippocampus and in frontal lobes (304), areas which 
play a crucial role in regulating learning and memory functions (242). Estrogens have 
neurotrophic effects by protecting against beta-amyloid toxicity (305-307), an important 
etiological factor in Alzheimer's disease. Estradiol can induce BDNF expression and the 
effects of estradiol in hippocampus may be mediated by BDNF (308). In some animal 
experiments, estrogen treatment has increased BDNF expression in hippocampus (309-
311). However, other studies have shown no effect of estrogen treatment on BDNF 
mRNA in hippocampus (312) or cortical regions (309,312,313). 
   Progesterone is also suggested to be neuroprotective by increasing the expression of 
BDNF mRNA and protein (314). Progesterone was shown to reduce tau 
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hyperphosphorylation, when administered either alone or in combination with estrogen 
(307), but had no effect on beta-amyloid accumulation (307). On the other hand, 
progesterone was shown to decrease BDNF levels (310) and to reverse the increase in 
BDNF levels initiated by estrogen treatment (315). 
   Androgen receptors are also found in brain regions that are important for learning and 
memory (316). Low testosterone levels were detected in patients with mild cognitive 
impairment or Alzheimer's disease (217). On the other hand, testosterone has been 
suggested to have neurotrophic and neuroprotective effects and to protect against beta 
amyloid deposition and phosphorylated tau proteins (217).
  However, the interrelationship between sex hormones and cognitive function remains 
unclear. There is an important gender difference in the rate of hormonal changes with 
ageing: in menopausal women estradiol falls to nearly undetectable levels, whereas in 
healthy men testosterone production declines slowly (316). Hormone replacement 
therapy may enhance cognitive function if the timing for treatment is optimal, i.e. on 
postmenopause or soon after it but further studies are needed (304,317,318).
   Further long-term human studies in general population are needed to confirm these 
novel results. In addition, randomized controlled trials are needed to provide further 
evidence for the effects of life-style factors such as exercise and diet on BDNF and 
cognitive function in ageing people. 
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7 CONCLUSIONS AND FUTURE IMPLICATIONS
* Metabolic syndrome and of the single risk factors low HDL cholesterol may be 
significant contributors to poor memory. To what extent improving the metabolic 
profile may prevent or postpone cognitive impairment remains to be shown in 
adequately planned and conducted randomized controlled trials in various intervention 
modalities.
* Increased carotid IMT, used as a surrogate measure of atherosclerosis, appears to 
predict an increased risk for cognitive impairment, particularly poor memory and 
cognitive speed, in elderly women. These findings add evidence that preventive actions 
against atherosclerotic progression may be important also with regard to cognitive 
impairment. 
* High serum hsCRP concentration was associated with an increased risk of poor 
memory, thus supporting the role of chronic low-grade inflammation in the processes 
leading to cognitive impairment.   
* The present study indicated that decreased plasma BDNF level is associated with 
impaired memory and general cognitive function in ageing women. While the present 
study may have identified a potentially important determinant of cognitive function in 
women, our cross-sectional findings need to be confirmed. 
* The investigated vascular status indicators were associated with specific cognitive 
tests, but not with crude global cognitive performance (measured with MMSE), 
highlighting the importance of sensitive cognitive measures in this kind of studies. 
* These cohort studies highlight the role of modifiable risk factors in the development 
of cognitive impairment and provide additional support to the current efforts of health 
care professionals to effectively prevent these metabolic and cardiovascular disorders.  
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